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Abstract
Boron Neutron Capture Therapy (BNCT) is based on the nuclear reaction that occurs when 
10B loaded tissue is irradiated with thermal neutron yielding high linear energy transfer a 
particles and recoiling 7Li nuclei .Neutron sources for BNCT are currently limited to research 
nuclear reactors. However most reactors are not in close proximity to hospitals and their use 
for clinical trials can be difficult. High energy photon beams from medical Linear 
accelerators produce undesirable neutrons, beside the clinically useful electron and photon 
beams, neutrons are produced from the photonuclear reaction of high energy photons with 
high Z-materials making the accelerator head. Such neutrons have been studied extensively, 
both in measurements and Monte Carlo calculations mainly from the point of radiation 
protection. In this work the neutron component from high energy medical linear accelerator, 
dose, and fluence had been studied for the purpose of shielding patient, staff and the general 
public from the contaminant neutrons. In this work one major finding is the increase of 
neutron yield from the medical linac head when jaws are open compared when jaws are 
closed. Making use of already installed high energy linacs in hospitals used primarily for 
high energy electron and photon (bremsstrahlung) therapy for neutron production for use in 
BNCT will be advantageous in the sense that their use is much more acceptable to the public 
than the use of reactors. It will also mean fewer complications with respect to patient 
movement and management and will be cost effective. To consider the feasibility of this 
Monte Carlo simulation of a voxalized head phantom have been undertaken, comparing a 
reactor source to a medical linac source and comparing different moderator modalities.
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Introduction
Chapter 1 : Thesis Introduction
1.1. Introduction
Cancer is a leading worldwide health problem, accountable for more than 2.9 million 
mortalities in women and 3.8 million in men per annum(IARC 2002). In the UK more than
284,000 people are diagnosed with cancer every year(CRUK 2008). With more than 200 
classified forms of cancers, four of them, breast, lung, large bowl and prostate cancers make 
half of the new cases registered in the UK, figure 1.1. In 2005 alone, cancer was responsible 
for more than 153,000 deaths a 27% of all deaths in the UK, totalling 29% for males and 25% 
in females. Lung cancer scored the highest mortality rate causing nearly one in five of all 
cancer deaths. With 10% of all deaths, large bowel cancer was the second most common 
cause of cancer death and, at 8% , breast cancer was the third most common cause of cancer 
death in all persons (CRUK 2007).
Figure 1. 1 The most common cancers in the UK in 2004 excluding non-melanoma skin 
cancer (CRUK 2008)
Globally, cancer is an increasing economic burden. In England, the NHS expenditure on 
cancer is around £4.35 billion a year. Overall, England spends 5.6% of the health budget on 
cancer, compared to 7.7% in France, 9.2% in the United States and 9.6% in Germany (DoH 
2007). Treatment of cancer is performed mainly through surgery, chemotherapy or 
radiotherapy or by any combination of the three. In a review by the Swedish Council on
1
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Technology Assessment in Health Care involving more than 700,000 patients, about 49% of 
curable cancers are cured by surgery, 40% by radiotherapy alone or in conjunction with other 
methods, and 11% by chemotherapy(SBU 1996; Kunkler 2004). In 2005, radiotherapy in the 
UK contributed to an estimated 5% of the total costs of cancer care compared to 22% 
incurred by surgery and 18% by chemotherapy(DoH 2007), figure 1.2.maldng radiotherapy a 
much more cost effective choice of treatment.
Radiotherapy’s focal aim is to destroy cancerous cells in the treatment volume with targeted 
ionizing radiation, this can be achieved either by external beam therapy or by brachytherapy 
where radioactive seeds are placed next to or surgically inserted to tumour site, Medical 
linear accelerators (linacs) are the most commonly used in external therapy modalities and 
are the workhorses of radiotherapy. Most linacs provide an option of either electron or photon 
beam with variable energies; the higher the energy of the beam the more penetrating it will 
be and thus ensure delivery of maximum dose to neoplasmic deep-seated tissues sparing skin 
and other superficial healthy tissues. In the UK there were 199 medical linac by 2002(RCR 
2003) and there is a progressive trend to replace older low energy linacs with high energy 
linacs( >10 MV) in order to cope with the increasing average size of patients so to deliver the 
right dose on site to large patients. However high energy linacs produce undesirable and 
unaccounted for neutrons which add up to the total dose received by a patient.
Neutrons are produced through the photonuclear reaction of high energy photons and to a 
lesser extent electrons with the materials comprising the linac head. Photonuclear induced 
neutrons have been the subject of a plethora of studies spanning the last 30 years (McCall 
1979; Pearson 1979; NCRP 1984; McGinley 1989; Hosseini-Ashrafi 1990; Mao 1997; 
Followill 2003; Kim 2007) , both through experimental measurements and by the use of 
Monte Carlo calculations mainly from the point of radiation protection.
2
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Figure 1. 2  Estimated total NHS spend on radiotherapy vs. other costs o f  cancer care for 
2005/2006 ,data from (DoH 2007)
1.2. Brain Tumours and BNCT
Brain tumours occur more commonly in men with a male:female ratio of 1.2:1.0. They 
constitute 1.8% of male cancer incidence in the UK and 2.6% of male cancer mortality. With 
such a low incidence of primary tumours they are still responsible for 7% of the years of life 
lost from cancer before the age of 70(CRUK 2003; CRUK 2007). Gliomas are a group of 
tumours comprising almost 60% of total brain malignancies; Astrcytomas are the most 
common type of gilomas and the most aggressive form is the Glioblastoma Multiform 
(GBM). For brain tumours, the five-year age-standardised relative survival for adults 
diagnosed between 1996-1999 was 12% for males and 15% for female, in England and 
Wales(CRUK 2004) making it one of the worst tumours resistant to therapy. Furthermore, 
despite the recent advance in diagnosis the median life expectancy for GBM is still 
unchanged at 12 months , only 5% or fewer will be alive after 5 years of diagnosis(Markert 
2005).
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Boron Neutron Capture Therapy (BNCT) is a treatment modality that was initially developed 
for GBM treatment.The BNCT principle is to aim a neutron beam of thermal/epithermal 
energy at ,0B loaded neoplasmic cells. Upon capture in boron, short range high energy 
transfer alpha and lithium-7 particles are released within the cell parameters leading to 
consequent DNA damage. Though being a cellular targeted therapy, and hence a desirable 
method of radiation delivery to such resilient cancerous cells, one of BNCT’s limitation is the 
clinical availability of suitable neutron sources. Currently, clinical trials on BNCT take place 
using research reactors, which is a further restraint as the technology is available only in a 
limited number of countries and yet reactors are not located in close proximity to hospitals 
restricting patient accessibility. Medical linear accelerators on the other hand are purposely 
built in hospitals and are widely spread worldwide. In this work the neutrons produced from 
high energy medical linear accelerators, have been assessed by measuring neutron fluence 
and dose around a 15MV Varian Clinac 2100C linac located in the St Luke’s Centre of the 
Royal Surrey County Hospital. Calculations were also performed using the MCNPX 
2.5.0(Pelowitz 2005) Monte Carlo code to determine neutron fluence from linacs as well as 
the spectral variations with variant modifiers and in different phantoms in order to evaluate 
the possible use of these neutrons for BNCT.
1.3. The Monte Carlo Method
The Monte Carlo method is a well established computational technique for solving 
sophisticated natural phenomena such as radiation transport through the use of random 
sampling. In the case of the radiation transport problem the Monte Carlo obtains answers by 
simulating particle histories and recording predefined user specified tallies without the need 
to solve transport equations deterministically which means that individual probabilistic events 
that comprise particles interaction processes are simulated in sequence. The probability 
distributions governing these events are statistically sampled to describe the total 
phenomenon. This statistical sampling requires selection of random numbers from a random 
number generator- analogous to throwing dice in a casino - hence the name “Monte Carlo”. 
In a given radiation transport Monte Carlo simulation each particle emitted from a source is 
followed throughout its life to its death through all possible interactions, using transport data. 
Probability distributions are randomly sampled for each interaction to determine the outcome 
at each step of its life, and the user specified tallies are recorded with its associated 
uncertainties.
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There are several Monte Carlo codes in use for radiation transport, some are very specific and 
some are more general, in this work MCNPX 2.5.0 was used to simulate radiation interaction 
in the linear accelerator head and in phantoms. MCNPX is a general purpose Monte Carlo 
radiation transport code that hacks nearly all particles at nearly all energies. It is an extension 
of its predecessor (MCNP) to all particles and all energies. It includes an improvement of 
physics simulation models, an extension of neutron, proton, and photonuclear libraries to 150 
MeV(Pelowitz 2005). MCNP(X) geometry is defined by an arbitrary three-dimensional 
configuration of materials in geometric cells created by Boolean combinations of first-degree 
and second-degree surfaces and fourth degree elliptical tori. MCNP(X) uses continues- 
energy nuclear and atomic data libraries. The primary sources of nuclear* data are evaluations 
from the Evaluated Nuclear* Data File (ENDF) system, the Evaluated Nuclear* Data Library 
(ENDL) and the Activation Library (ACTL) compilations.
The MCNP(X) code provides an output file of tallies normalized to be per* starting particle as 
well as the associated relative error R, defined to be one estimated standard deviation of the 
mean S% divided by the estimated mean x. For a well-behaved tally, R will be proportional to 
1 /V N  where N  is the number* of histories. As a result, to halve R, one must increase the total 
number of histories fourfold. This error relates to the precision of the Monte Carlo simulation 
and not the accuracy of the generated results compared to the true physical 
values(Briesmeister JF 2000).
1.4. Thesis breakdown
Chapter two reviews ionizing radiation quantities and units in use for neutron dosimetry.
Chapter three provides a review of the Medical linac working principle and the photonuclear 
production in the linac head.
Chapter four is on neutron dose surveys in and around medical linac treatment rooms in 
comparison to analytical methods.
Chapter five is on neutron fluence measurements around a linac using activation foils.
Chapter six evaluates through Monte Carlo simulations in a mathematical Snyder phantom 
and in a voxel based Zubal phantom the in-hospital utilization of a Medical linac as a source 
of neutrons for BNCT
Chapter seven presents overall conclusions and suggested future work.
5
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Quantities and Unit in Neutron Dosimetry
Chapter 2 : Quantities and Units in Neutron Dosimetry
2.1 Quantities in Radiological Protection
Throughout the world, there have been ongoing investigations by several organisations to 
effectively quantify the biological impact of radiation on the human body over many years. 
Two organisations were formed: The International Commission on Radiation Units and 
Measurements (ICRU), and The International Commission on Radiological Protection 
(ICRP), both emerged from the umbrella of the International Society of Radiology in 1928 
and both have provided internationally accepted recommendations on radiation quantities, 
units, measurements and protection regulations and recommendations. In the UK, the 
International Commission’s recommendations have been incorporated into the Ionising 
Radiation Regulations 1999 (IRR’99), as advised by the Health and Safety Executive (HSE). 
The National Council on Radiation Protection and Measurements (NCRP) in the United State 
plays a similar role by providing US-wide regulations on radiation protection and works in 
partnership with the ICRU, ICRP and the Federal Radiation Council.
The quantities defined by these international organizations have been constantly evolving 
over time and the relationships between some of these essential quantities are illustrated in 
figures 2 .1  and 2 .2 .
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Figure 2. 2  System o f dose quantities for use in radiological protection (ICRP 2007)
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2. 2 Physical Quantities
These quantities are characteristic of all types of radiation. They apply in free space as well 
as matter. Each is listed below:
Flux:
Flux is fluence per unit time, dN/da dt 
Kerma:
The kerma, K, (Gy) is the quotient of dEXr by dm, where dE^ is the sum of the kinetic energies 
of all charged particles liberated by uncharged particles in a material of a mass dm:
Absorbed Dose:
Absorbed dose, D, (Gy) is the basic physical dose quantity in radiation protection and is 
defined as the quotient of de by dm, where de is the mean energy imparted by ionizing 
radiation deposited to matter of mass dm:
Fluence:
Fluence, (p, (nf2) is defined as the number of particles of interest, dN, passing through a 
sphere with cross-sectional area, da:
(2 .1 )
(2 .2 )
dm
(2.3)
Absorbed dose is the most fundamental dosimteric quantity to be correlated with biological 
effects of radiation.
11
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2.3 Protection Quantities
Different radiations induce different amounts of damage to biological tissue. For this reason, 
the basic quantity of absorbed dose may not always be an effective measure of the effects of 
radiation. It is also the case that different organs/tissues may be more sensitive to radiation 
than others. The International Commission on Radiation Protection (ICRP) has established 
two quantities to account for such variations: equivalent dose (incorporating radiation 
weighting), and effective dose (incorporating tissue weighting). The most recent set of 
protection quantities was recommended in ICRP No. 103 (2007).
Equivalent Dose:
Equivalent dose, H rr, is the averaged absorbed dose applied in the volume of a specified 
organ/tissue T, due to radiation of type R (Drr) combined with a weighting factor, wr, 
specific to the type of radiation involved:
H T , R  ~  ^ R ^ T . R  ( 2 j 4 )
Radiations which impart more energy to the medium through which they travel tend to cause 
greater biological damage, and so are weighted accordingly. In the ICRP publication 
60(ICRP 1991) neutrons within the 100 keV to 2 MeV region were given a high radiation 
weighting factor given that they impart more energy upon interaction with the human body, 
(Table! 1).
Table 2.1 Radiation weighing factor (ICRP 1991)
T y p e  a n d  e n e r g y  ra n g e  R a d ia tio n  w e ig h tin g  fa c to r  h>r
Protons, other than recoil protons, 5
energy > 2 MeV
Alpha particles, fission fragments, heavy 20
nuclei
12
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Table 2.2 Radiation weighing factor ICRP 2007 recommendation
Radiation type Radiation weighting factor h>r
Photons 1
Electrons and muons 1
Protons and charged pions 2
Alpha particles, fission fragments , heavy 
ions
20
Neutrons A continuous curve as a function of  
neutron energy (figure2.3 and equation 
2 .6 )
For a mixed radiation field, the protection quantity equivalent dose, Hj in an organ or tissue 
is given by summing the dose components for each type of radiation present:
(2.5)
R
The unit of equivalent dose is J kg' 1 and has the special name Sievert (Sv).
In the ICRP publication 60 (ICRP 1991) the radiation weighting factor wr for neutrons was 
defined by a step function in relation to neutron energy peaking at ~ 0.8 MeV. It is now 
recommended that the radiation weighting factor for neutrons be defined by a continuous 
function (Figures 2.3 and 2.4) respectively (ICRP 2007)
The most significant changes in ICRP publication 103 (2007) compared to the data in 
publication 60 are the decrease of wr in the low-energy range, which takes account of the 
large contribution of secondary photons to the absorbed dose in the human body, and the 
decrease of wr at neutron energies above 100 MeV.
The following continuous function in neutron energy, En (MeV), was recommended for the 
calculation of radiation weighting factors for neutrons:
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En < 1 MeVr 2.5 + 18.2e“[In(E")]2/ 6'
WR = 5.0 + l7 .0e“[ln(2^ )]2/6' 1 MeV < En < 50MeV
*2.5 + 3.25e“[ln(0-04^ 2/6'
(2 .6)
En > 50MeV
Neutron energy / MeV
Figure 2. 3 Radiation weighting factor, w& fo r  neutrons versus neutron energy. (ICRP 2007)
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Figure 2. 4 Radiation weighting factor w& fo r neutron versus neutron energy, Step function 
and continuous function given in Publication 60 (ICRP 1991) and function adopted in the 
ICRP 2007 recommendation(ICRP 2007)
Effective Dose:
Effective dose, E, (Sv) is the summation of the equivalent doses (Hf) to all radiosensitive 
tissues multiplied by the appropriate tissue weighing factor wr,
E  = Y , wtH t(2.7)
T
Table 2.3 lists tissue weighting factors as published by the ICRP in publication 60 (ICRP 
1991) and in publication 103 (ICRP 2007), with the organs which underwent revision to their 
weighing factors in bold.
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Table 2.3 Tissue weighting factors, w t , in the ICRP 1991 and the ICRP 2007 
recommendations.
ICRP 1991 ICRP 2007
Tissue or organ Tissue 
weighting 
factor, wt
Tissue or organ Tissue 
weighting 
factor, wt
Gonads 0.20 Gonads 0.08
Lung 0 .12 Lung 0 .12
Stomach 0 .12 Stomach 0 .12
Colon 0 .12 Colon 0 .12
Stomach 0 .12 Stomach 0 .12
Breast 0.05 Breast 0.12
Thyroid 0.05 Thyroid 0.04
Liver 0.05 Liver 0.04
Oesophagus 0.05 Oesophagus 0.04
Bladder 0.05 Bladder 0.04
Skin 0.01 Skin 0.01
Bone surface 0.01 Bone surface 0.01
Remainder: adrenals, 0.05 Brain 0.01
brain, Lower Large Salivary glands 0.01
Intestine, Upper Large Remainder: adrenals, 0.12
Intestine, Kidneys, extrathoracic tissue, gall
muscle, pancreas, spleen, bladder, heart, kidneys,
thymus, uterus lymphatic nodes, muscle, oral 
mucosa, pancreas, prostate, 
small intestine, spleen, thymus, 
uterus/cervix.
2.4 Operational Quantities
Direct measurement of the radiation protection quantities listed above is not feasible, for this 
puipose, the ICRU had introduced a set of operational quantities which is measurable and is 
correlated to the protection quantities. For neutron dosimetry the ICRU operational unit is 
the dose equivalent(ICRU 2001).
In order to implement dose-equivalent, a standard phantom has been produced called the 
ICRU sphere. It is 30cm in diameter, with a density of 1.0 gem'3,consisting of material 
equivalent to soft tissue with a mass composition of 76.2% oxygen, 11.1% carbon, 10.1% 
hydrogen, and 2.6% nitrogen (ICRU 1980).
16
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Dose equivalent
Dose equivalent is defined as the product of absorbed dose (D) and the radiation quality 
factor (Q) at a specified point of interest in tissue.
H  = QD (2.8)
The unit for AT is Joule per kilogram (J kg-1), given the name, Sievert (Sv).
Ambient Dose Equivalent:
Ambient dose equivalent, H*(d), (Sv) at a point in a radiation field is the dose equivalent that 
would be generated by the corresponding expanded and aligned field in the ICRU sphere at a 
reference depth, d, on the radius opposing the direction of the aligned field. An H*(d) of 10 
mm, i.e. H*(10) is the quantity of choice for characterization of strongly penetrating radiation 
(such as neutrons). For weakly penetrating radiation an H*(d) of 0.07 mm i.e. H*(0.07) is 
recommended.
Directional dose equivalent
Directional dose-equivalent, H ’(d, 0),at a point in the radiation field, is the dose-equivalent 
that would be produced by the corresponding expanded field in the ICRU sphere at depth, d, 
on a radius in a specified direction Q, in a field of constant directional fluence and energy 
distribution. The same reference depth (d) recommendations follow as ambient dose 
equivalent for strongly and for weakly penetrating radiation.
Personal Dose equivalent:
Personal dose-equivalent, Hp(d'), (S v ), at a point in the radiation field is the dose equivalent 
in soft tissue at depth, d, below a specified point on the body. Recommended reference depth 
(d) for strongly and for weakly penetrating radiation is the same as ambient dose equivalent.
Linear Energy Transfer
Lineal* Energy Transfer (LET) is a term firstly adopted by Zirkle et al (Zirkle 1952) to 
describe the amount of energy deposited along the track of a particle or photon and is 
measured in keV /pm. LET is an important quantity when assessing cell damage from 
radiation because the amount of damage incurred by radiation on a cell depends on the 
number of ionizing events produced by the radiation in the proximity of the cell DNA.
17
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Radiation damage along a particle track is caused either by direct mechanisms in which DNA 
molecules are ionized by the particle or by indirect mechanisms in which free radicals 
produced by the ionizing particle. About 80% of each cell is made up of water, so the 
majority of radiation interactions involve the ionization of water molecules and the formation 
of free radicals which in turn causes DNA damage (Petti 1994) High LET radiation produces 
many more ion pairs along its path than does Low LET and thus exerts direct damage on the 
cellular DNA; low LET radiation damage to cells is induced mainly indirectly through free 
radicals(Russell 2007).
Due to the 1/E dependence of LET, protons, alphas, and heavier particles exhibit a very high 
LET at the end of their range, resulting in a sharp “ Bragg peak” (Fig. 2.5).
Figure 2. 5  Depth-dose curves in water for various types ofphotons and particles commonly 
used in radiation therapy (arbitrary normalization) (Kraft 1999)
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Relative biological effectiveness (RBE)
In radiobiology, the relative biological effectiveness (RBE) is defined as the ratio of the 
absorbed dose of a reference source of radiation (e.g., X-rays) to that of the test radiation that 
produces the same biological effect. RBE for any given radiation was originally defined “by 
comparison with the y radiation from radium source filtered by 0 .5 mm of platinum”(Taylor 
1984). In radiation protection however, RBE is only used in terms of the derived quantities, 
quality factor, Q (?), and radiation weighting factor, wr.(ICRP 2003). 0  (?) is a function of 
unrestricted LET specified by the ICRU as: L = d E /d x  , where dE is the energy lost by a 
charged particle in traversing a distance dx (ICRU 1980).
Compound biological effectiveness (CBE)
In BNCT, because of the inhomogeneity of the distribution of the boron compounds and the 
short range of the a and lithium particles, the concept of absorbed dose cannot be applied and 
therefore the RBE cannot be defined. Only the product of the RBE and boron distribution can 
be assessed for a given tissue and experimental conditions. This product is termed Compound 
Biological Effectiveness (CBE) and is drug dependent.(IAEA 2001)
19
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Chapter 3 : Medical Linear Accelerator 
3.1. Introduction
Radiation therapy is widely used to treat tumours in conjunction with surgery, and/or 
chemotherapy, the Medical linear accelerators (linac) is the most common device used for 
such treatment. A medical linac can be broken into three main parts, (1) high voltage supply 
and pulse modulator system (2 ) accelerator wave guide and beam defining system, and (3 ) 
computing and control system, figure 3.1. In a linac, an isocentric gantry in conjunction with 
a manoeuvrable rotating treatment couch allow for the radiotherapy beam to be delivered 
from all possible directions with no movement of the patient. Table 3.1. compares various 
types of particle-beam modalities in contrast to linacs, their characteristics, and the type of 
cancers generally treated with each modality.
Table 3.1 Summary o f external beam radiotherapy options for malignant tumours(Petti 1994)
Particle TumourCharacteristics
Energy
deposition
Bragg
peak
Radiation
source
Cost 
$ million
f
Photons
Electrons
Rapidly
growing,
oxygenated
Superficial
Low LET 
Low LET
No
No
Electron
linac;microtron
Electron linac; 
microtron
1-2
1-2
Protons
Fast
neutrons 
Heavy ions
Pions
Slow
neutrons
Early stage, 
near-critical 
structures
Low LET Yes Synchroton;cyclotron 10-15
Slow growing, 
hypoxic High LET No
Proton linac; 
cyclotron; 8 - 10
Same as fast 
neutrons High LET Yes Synchrotron 40
Same as fast 
neutrons High LET Yes
Proton linac; 
cyclotron 35—40
Glioblastoma; Very high Low energy
Some LET No accelerator; 1 - 2
melanomas (BNCT) nuclear reactor
t  In 1992 US$ term, not including building and clinical equipment cost.
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3.2 Linac working principle
Simple electrostatic accelerator (electron gun) inject electrons into an accelerating waveguide 
figure 3.2,an electron gun comprising a heated cathode at a negative potential and a 
perforated grounded anode, electrons are thus emitted from the heated cathode (Edison effect) 
focused into a pencil beam and then accelerated toward the anode and to the accelerating 
waveguide.
Gantry 
ax I*
270* banding 
magnet
Figure 3. 1 Medical linac in relation to patient plane and isocentre(Podgorsak 2006)
The high power microwave radiation used for electron acceleration is produced in the 
accelerating waveguide by two components: the (radioffequency) RF power source and the 
pulsed modulator. The microwave generated in the RF power source is in the frequency range 
from 1CF MHz (L band) to 104 MHz (X band), with the majority of medical linac running at 
2856 MHz (S band).The microwave is generated by a klystron or a magnetron, the choice 
between which is a matter of practical convenience, magnetrons are smaller in size, 
operate at a lower voltage and can be fitted into the rotating gantry, klystrons however are 
bulkier, operate at higher voltages and hence can not be fitted on the gantry(Greene 1997). 
The pulsed modulator produces pulses with high voltage (~50kV), high current, and short 
duration (~4ps) (Podgorsak 2006)
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Electrons are accelerated in the waveguide through energy transfer from the high RE field to 
the required electron energy. The accelerating waveguide is divided up into a series of 
cylindrical cavities by series of disks with circular holes at the centre placed at equal intervals 
along the waveguide tube, which at any time during the acceleration of an electron are either 
negatively or positively charged.
Primary
collimators
Flattening 
filter 
Dual ion 
chamber 
Upper
Figure 3. 2 Schematic diagram o f an medical linac with waveguide(Dyk 2005)
In x-ray therapy mode, the accelerated beam of pulsed high-energy electrons is directed to the 
treatment head where it is stopped and x-rays are produced by bremsstrahlung. The final x- 
ray beam is then modified and filtered before being delivered to the patient. When used in 
electron mode, the electron beam is targeted onto scattering foils in the treatment head before 
being verified and finally directed to a patient plane.
To date, medical linear accelerators had evolved through five distinct generations(Podgorsak 
2006):
•First Generation Low energy photons (4-8 MV): straight-through beam; fixed flattening 
filter; external wedges; symmetric jaws; single transmission ionization chamber; isocentric 
mounting.
•Second Generation Medium energy photons (10-15 MV) and electrons: bent beam; 
movable target and flattening filter; scattering foils; dual transmission ionization chamber;
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electron cones.
• Third Generation High energy photons (18-25 MV) and electrons: dual photon energy and 
multiple electron energies; achromatic bending magnet; dual scattering foils or scanned 
electron pencil beam; motorized wedge; asymmetric or independent collimator jaws.
•Fourth Generation High energy photons and electrons: computer-controlled operation; 
dynamic wedge; electronic portal imaging device; multileaf collimator.
• Fifth Generation High energy photons and electrons: photon beam intensity modulation 
with multileaf collimator; full dynamic conformal dose delivery with intensity modulated 
beams produced with a multileaf collimator (IMRT); on-board imaging for use in adaptive 
radiotherapy.
3.3 Linac treatment head
The treatment head is the part of linac where the clinically useful treatment beam, either 
x-ray or electron, is finally generated, the main parts of the treatment head are, x-ray 
target, primary collimators, flattening filters, movable collimators, monitor chamber, and 
multileaf collimators. Figure 3.3 shows a block diagram o f linac head components,
24
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Target
Primary Collimator
Flattening Filter
Ionisation chamber
Y -jaw
Movable collimators
X- jaw
Multileaf collimators
Figure 3. 3 A block diagram o f linac treatment head 
3.3.1 X-ray target
The target is a disc-shaped composite material commonly made of a tungsten alloy fitted into 
a heat dissipation block made of copper. The thickness and the atomic number of the target 
determines the photon spectrum generated. For a thin target, the mean photon energy will be 
greater than for a thick target, but the output photon will be contaminant with electrons, a 
thicker target will decrease the amount o f unwanted electrons in the beam but it will also 
soften the emitted photon spectrum. To get rid of most of the electrons in the photon beam, 
a low atomic number absorber back-up plate made of materials like carbon is employed 
on the back of the target.
3.3.2 Primary collimators
Made of either a conical lead filled steel casting or tungsten-copper alloy block, the primary 
collimators function is to define the maximum dispersion angle of the radiation beam to a 
maximum circular field which is further defined with the movable rectangular collimator 
consisting of two upper and two lower independent jaws.
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3.3.3 Flattening filters
As the name suggests, a flattening filter is used to give a flatter profile to the x-ray beam and 
reduce the on-axis intensity, i.e. harden the beam, it is a cone-shaped device and thus 
differentially absorbs the x-ray radiation towards the beam centre. For linacs operating at 
energies above 15 MV low atomic number materials such as aluminium are preferable as they 
cause less beam softening than high atomic number materials; however, at such high energies, 
and for the linac to support a maximum field of 40x40 cm2 at 100 cm from the target, the 
required flattening filter will be several centimetres thick at the centre and this will be hard to 
accommodate given the limited space constraints in the linac head (Podgorsalc 2006). For this 
reason copper, iron or stainless steel are more suitable. Varian 2300 C/D 18 MV uses conical 
shaped iron flattening filter (Zanini 2004) as well as the Siemens Mevatron KD-S linac 
18MV (Barquero 2005)
3.3.4 Movable collimators
Their function is to truncate the beam into a rectangular field, movable collimators are pairs 
of independent upper and lower jaws (X and Y jaws in figure 3.3.) These collimators move 
in an arc in the x and y direction, as described by the field size, for this they are made of lead 
alloyed with other metals in order to improve the mechanical properties. The rectangular or 
square field produced is of a maximum dimension of 40x40 cm2, 100 cm from the x-ray 
target at the linac isocentre.
3.3.5 Monitor chamber
The monitor chamber consists o f a set o f parallel-plate multi-channel ionization chambers 
which monitor dose rate and dose distribution in the irradiation field. As photons pass 
through the ionization chamber they induce current proportional to the number of photons 
passing per unit time, this current is in turn proportional to the dose rate at the patient or 
phantom plane. The beam monitor current is calibrated in terms of dose rate in the 
phantom so as 1 MU equal to 1 cGy at the depth of maximum dose in a 10x10 cm2 field at 
100 cm SSD.
3.3.6 Multileaf collimators
The multileaf collimators (MLC) allow for radiations beams to be shaped in irregular outlines 
as opposed to just rectangular fields offered by older generations of linacs, this is essential to
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spare patient healthy or otherwise sensitive tissues while concentrating the irradiation on the 
tumour volume. In the Varian 2300 C/D there is a set of 40 tungsten leaf pairs, each leaf has 
its own motor so as to provide independent leaf movement and so almost unlimited shape 
formation.
3.4 Neutron contamination in Medical Linac
3.4.1 Introduction
Medical linear accelerators operating above 10MV inherently produce neutrons through the 
photonuclear* reaction of high energy photons with high Z materials in the linac head, when 
the photon energy is higher than the separation energy of neutrons, neutron production is 
inevitable. The separation energy for lead and tungsten, the major elements in the linac head 
is in the region of 8MV.
3.4.2 Neutron interaction
Neutrons are uncharged particles and therefore are not influenced by the Coulomb force that 
dominates the interactions of charged particles with matter; neutrons interact directly with the 
nuclei of the material. As in the case for other particles, neutron interactions fall into two 
broad categories: scattering or absorption. In term of their kinetic Ek energy neutrons can be 
classified into 3 broad categories,
Thermal neutrons, EK < 0.025 eV,
Epithermal neutrons 0.025 <£±<0.1 MeV,
Fast neutrons Ek >0.1 MeV.
3.4.2.1 Elastic Scattering
In elastic scattering a neutron collides with a nucleus of mass M  that recoils with an angle ® 
with respect to the neutron initial direction of motion, the incident neutron transfers some of 
its energy to the target nucleus (figure 3.4). Kinetic energy and momentum are conserved in 
the interaction. Elastic scattering is more probable for light elements such as hydrogen.
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M ,u2
Figure 3. 4 Elastic neutron scattering; neutron o f mass mn and velocity vy collides with a 
nucleus o f mass M  resulting in a scatter neutron with a scattering angle 6 and a velocity o f  
ui, the target nucleus recoil with an angle <P and a velocity o f  ui
3.4.2.2 Inelastic scattering
Inelastic scattering takes place when the energy of the incident neutron is sufficiently high. 
The neutron is first captured by the nucleus and then re-emitted with a lower energy in a 
direction that is different from the incident neutron direction (Podgorsak 2006). The nucleus 
is raised to an excited state and will return to ground state through the emission of high 
energy gamma rays. This process is illustrated below in equation 3.1:
n + jX  - > A+) X‘ -> AZX ' + n -> (31)
where:
zX  is the target nucleus,
A+zY* is an unstable compound nucleus, 
zX* is an excited target nucleus
3.4.2.3 Radiative capture
Also referred to as neutron capture or (n,y) reaction, radiative capture is the most probable 
reaction for thermal neutrons, the incident neutron is absorbed by the target nucleus which
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undergoes excitation and then de-excites to ground state emitting a prompt y-ray.
Incident
neutron
Inelastic Scattering
f
y (prompt)
• >  excited 
state
Radiative Capture
Incident
neutron
 > excited
y (prompt)
Figure 3. 5  Summary o f neutron interaction o f interest in medical linac environment
3.4.3 Cross section
For a collimated neutron current J (J is the number of neutrons crossing a unit area surface 
perpendicular to the beam direction per unit time) falling on a material which contains N 
identical atomic nuclei per unit volume Assuming that the current penetrate the sample 
practically without attenuation, the number of interactions (scattering and absorption) per unit 
time and unit area is xpx :
(3.2)
ip = JNg .
• • • • • 2 1 where ip is the collision density in cm' sec' and jc is the depth in the sample. The constant
o is called the interaction cross section. The cross section has unit of area and has been
traditionally measured in bams where 1 bam= 10'28 m2 . Scattering and absorption cross
sections are usually distinguished from one another (os and aa respectively), each is
composed of partial cross sections such as elastic and inelastic scattering, radiative capture,
etc. The sum of all partial cross sections is called the total cross section (Beckurts 1964):
ot= os + oa (3-3)
When multiplied by the number of nuclei N per unit volume, the cross section o is converted
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into the macroscopic cross section E
(3.4)
E = oN
It specifies the cross section per unit length and has the dimension of inverse length. It can 
be also considered as the probability that the neutron is scattered or absorbed in a imit length. 
The macroscopic cross section for neutrons is equivalent to the linear attenuation coefficient 
for photons.
3.4.4 The neutron mean free path X:
For a neutron striking a material, the probability that a nucleus in the material is hit is 
proportional to the path Ax in the material and equals S Ax. Consequently, the probability 
that the neutron transverse the path Ax without a collision is 1 —E Ax.
The probability that the neutron collides with a nucleus in the differential distance dx after 
traversing distance x is E dx e~1,x. The probability that it collides after any arbitrary path 
length is(Beckurts 1964):
f 0 e ~Ix  E d x  -  1  ■ (3 5)
Thus, the neutron mean free path for a collision, which is analogous to the attenuation 
coefficient for photons, is:
A — f ” x e~£x E dx  =  |  (3-6)
In solid materials, A for slow neutrons may be of the order of a centimetre or less, whereas 
for fast neutrons it is normally tens of centimetres.
If a neutron moves with a constant velocity v, the mean time between two collisions is:
T =  i  (3.7)
V
The number of such collisions per unit time is:
If there are n neutrons of velocity v per unit volume of a material, the number \j/ of events per 
unit time, per unit volume i.e. the reaction rate per unit volume is:
ip =  —  — n v T ,  (3-9)
r
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3.5 Photonuclear production in linac head
Neutron production in a medical linac operating in high energies can be considered to be 
unwanted extra dose to a patient, dose to medical staff and to the general public either from 
neutrons directly or from residual radioactivity resulting from interaction taking place. The 
production of neutrons is a result of the interaction of either electrons or photons with 
elements in the linac head or in the linac treatment room. Extensive studies on both 
measurements and simulations had been taken place to survey neutrons form different linac 
made and operating energies (McCall 1979; McGinley 1989; Rawlinson 2002; Ma 2008)
3.5.1 Photoneutrons
When a photon with high enough energy collides with a nuclide, it will be absorbed by the 
nucleus, elevating it to an excited state. If the photon’s energy is higher than the separation 
energy of the associated nucleons, competing de-excitation processes take place, the emission 
of a nucleon from the nucleus or the emission of a gamma ray. In the case of photoneutron 
production, which is often the most likely process at the higher energies, a neutron is emitted 
rather than a proton due to the fact that neutrons are uncharged and hence not affected by 
Coulombic forces. Therefore the separation energy of neutrons is lower than for protons.
The separation energy is also known as the threshold energy as it is the energy 'barrier' which 
must be crossed before a particular nucleon emission reaction is possible, (Krane 1988)
For a nucleus binding energy B, the neutron separation energy Sn is:
Sn — B(. z^ n ) -  A z^ n- i  ) =  [tti(4 z^ n- i  ) — m  (z^w) +  Tnn]c2 (3*10) 
The photonuclear reaction can be described as:
(3.11)
y + AX - ^ A'1X + n  + Q
Where y is the incident photon, X  is the target nucleus, A'lX  is the resultant nucleus, n is the 
neutron emission, and Q is the net energy difference between initial and final states.
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The threshold energy for this absorption reaction is given by (Krane 1988):
Ethld ~
(3.12)
Where M  is the mass of the target nucleus, mn is the neutron mass, Q is again the net energy 
difference. Q is negative to indicate the endothermic nature of the reaction, meaning 
minimum (threshold) energy is required for the process to take place.
A photon interaction might result in the emission of more than one neutron, or a combination 
of nucleons. These processes are annotated such that a single neutron emission is written as (y, 
n); a double neutron emission as (y, 2n); and so on up to (y, in). Similarly, examples of 
combination emissions include: (y, pn) for proton neutron photoproduction, and (y, a2n) for 
a-particle plus double neutron photoproduction. Each type of emission will have its own 
associated separation energy.
3.5.2 Electroneutrons
The same reaction, by photons, that can result in the production of neutrons can also occur by 
the interaction of an electron with the nuclide and is termed the electronuclear reaction (e,e'n). 
The cross section for the electronuclear reaction is much smaller than that of the photonuclear 
reaction, at least 10 times (Khan 1994). In this process, there are two distinct reactions(NCRP 
1984). In the first, an electron with incident energy E, undergoes bremsstrahlung scattering 
within the Coulomb field with an angle 6 of the target nuclide R figure 3.6. to produce a 
photon with an energy Ey = Et - E/., this product photon consequently induces a photonuclear 
reaction in the target nuclide A through (y, n).
Figure 3. 6 electronuclear neutron production through subsequent (y,n) reproduced from 
NCRP No. 79(NCRP 1984)
In the second reaction figure 3.7, the electron scatters through the Coulomb field of the
Electron
%
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nuclide creating a virtual photon, which interacts directly with the atom’s nucleus .
* " " > ©
Figure 3. 7 Eletroneutron production, reproduced from NCRP No. 79 (NCRP 1984)
The neutron separation energy(Sn) for most stable nuclei heavier than carbon lies between 6 
and 16 MeV (NCRP 1984) meaning that for most linear accelerators in clinical use 
photoneutron production, (y,n) is inevitable.
3.5.3 Giant Dipole Resonance (GDR)
In photonuclear production, the cross section starts from zero at the threshold, increases fairly 
quickly with increasing energy, to a maximum and then slowly decreases in a bell shape 
distribution. The shape of this peak is characteristic of resonance reactions and is called the 
Giant Dipole Resonance (GDR), this is attributed to the electric dipole absorption of the 
incident photon. Figure 3.8 through 3.10. show the photonuclear cross section of the most 
common isotope of tungsten, copper and lead the elements most often used in the linac head.
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184x W- lAEA-photonuclear-lanl
Photon Energy (MeV)
Figure 3. 8 Photonuclear cross section o f W-184, ,(y,n) threshold 7.41MeV.
X  63Cu fAEA-photonuclear-lanl
Photon Energy (MeV)
Figure 3. 9 Photonuclear cross section o f  Cu-63, ,(y,n) threshold 5.4 MeV.
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Photon Energy (MeV)
Figure 3. 1 0 Photonuclear cross section o f  Ph-208, ,(y,n) threshold 5.9 MeV
The total area under the resonance curve when plotted against photon energy (E) can be 
approximated by the dipole sum-rule (NCRP 1984):
r * 2 tt 2 e 2 fr N Z  N 7
[ <7 ( E )  dE  = ---------------------------- = 0 .06  -------- ( M eV  barns )
Jo Me A A
N Z
= 60   ( MeV mbarns )
A
where e is the charge on an electron, fr is Planck’s constant over 2k, M  is the average nucleon 
mass, c is the speed of light, N  is neutron number, Z  proton number, and A = N+Z. The GDR 
peaks at photon energies of 13 MeV to 25 MeV depending on the nuclide’s atomic weight 
with heavier nuclides generally having a lower energy GDR figure 3.11.
(3 .1 5 )
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Light elements have lower initial threshold energies for neutron separation, but the giant 
resonance peak of the (y,n) is typically higher than the energy range of photons produced in 
the linac. Photonuclear cross-sections are rather uniform as a function of mass number, with 
the heaviest isotopes having the greatest cross-section, with the lowest energy giant 
resonance peak figure 3.11. Thus the majority of the neutron production comes from 
photonuclear reactions within the collimator materials. These are heavy elements designed to 
provide maximum x-ray shielding and are thus made almost always of lead and tungsten 
alloys. In contrast, photonuclear- production in the lighter elements in the linac treatment 
room such as those found in the patient, couch or concrete, are almost insignificant.
Figure 3. 1 1 Mean giant resonance energies (NCRP 1984)
3.5.4 Photoneutron Spectra
In general neutrons produced through the giant resonance originate from two mechanisms, 
evaporation and direct emission, evaporation gives the largest contribution, have a distinctive 
energy spectrum analogous to a Maxwellian distribution and dominate the low energy region 
and are emitted isotropically. This process involves the excitation of the nucleus and the 
subsequent isotropic emission of a neutron in order to reduce the nuclear energy, with the 
distribution due to the variation in nuclear- temperatures.
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For the centre of mass reference frame, the evaporation spectrum follows the Maxwellian 
distribution of flux as a function of energy ®(E) and is given as:
Me k) =
(E /  \  f r j T )  
« / o x e  J
v
rji 2
(3.13)
J
Where T is the nuclear temperature in MeV, En is the energy of the emitted neutrons. The 
most probable energy is at E=T  and the average energy is at E=2T.
The direct emission neutrons dominate the higher energy region of the spectrum and have the 
following distribution(Tosi 1991):
( — ) d  =\DEnJ
InfJiMaxl
LEn+ArJ (3.14)
Where Emax is the maximum energy of the incident photons and An is the neutron binding 
energy. Such neutrons are usually emitted anisotropically with respect to the angle of the 
incident photon.The exact shape of the photo-neutron spectrum depends on the shape of the 
photon spectra, but assuming a mono-energetic flux of photons figure 3.12 shows a typical 
photo-neutron spectrum.
The energy spectrum in fig 3.12 shows two components. The lower energy peak around 1- 
2MeV (depending on photon energy and target material) and a bump in the higher energy 
region due to the direct reaction. This bump is much less pronounced than the main peak as 
direct emission neutrons constitute only around a tenth of the whole neutron spectrum 
(Hosseini-Ashrafi 1990)
Swanson(Swanson 1979) had calculated the maximum number of neutrons an electron can 
produce in interacting with semi-infinite slabs of several elements ranging from carbon to 
uranium which are thick enough to absorb an incident electron beam, whilst being thin 
enough to have a negligible effect on reabsorbing neutrons .
An escalation in neutron production can be observed from 10 MeV to 30 MeV after which a 
plateau level is reached by most elements, figure 3.13.
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Neutron energy (MeV)
Figure 3. 1 2  Photoneutron spectrum in comparison with fission spectrum(NCRP 1984)
Figure 3. 1 3 Neutron yields from semi-infinite targets as a function o f the incident electron 
energy (NCRP 1984).
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To collimate the treatment photon beam heavy Z materials such as tungsten and lead mostly 
made in alloys are used in collimators. To do this, they must provide exceptional photon 
shielding along the beam direction. Because of the high atomic number of these materials, the 
photoneutron production in the shielding is primarily through inelastic scattering (n, n'), and 
(n, 2n) processes, yet it is still possible for them to penetrate the treatment head. At lower 
energies (n, n') causes the greatest energy loss, whilst (n, 2n) production prevails at neutron 
energies above ~9MeV figure 3.14. and figure 3.15. The (n, 2n) process results in two 
neutrons with energies much lower than the one incident, and most of these neutrons will thus 
undergo inelastic scattering. Elastic scattering does not seem to contribute greatly to energy 
losses, but it does increase the neutron’s path-length raising the chances for the other 
processes to occur.
Energy <MeV>
Figure 3. 1 4 Neutron interaction cross-sections in lead for elastic scattering, inelastic 
scattering, and (n, 2n) production, from ENDF/B-6. plotted using MCNPX.
39
Cr
os
s 
Se
ct
io
n 
<f
a)
Photonuclear production in Medical linear Accelerators
Energy <MeV>
Figure 3. 1 5  Neutron interaction cross-sections in tungsten for elastic scattering, inelastic 
scattering, and (n, 2n) production, from ENDF/B-6.1 plotted using MCNPX.
40
Photonuclear production in Medical linear Accelerators
References
Barquero, R., Mendez, R., Vega-Carrillo, H. R., Iniguez, M. P., et al. (2005). "Neutron 
Spectra AND Dosimetric Features Around an 18 MV Linac Accelerator." Health 
Physics 88(1): 48-58.
Beckurts, K. H. and Wirtz, IC. (1964). Neutron Physics. Berlin, New York,, Springer.
Dyk, J. V, (2005). The Modem Technology of Radiation Oncology: A Compendium for 
Medical Physicists and Radiation Oncologists Medical Physics Publishing
Greene, D. and Williams, P. (1997). Linear Accelerators for Radiation Therapy, Institute of 
Physics.
Hosseini-Ashrafi, M. E. (1990). The Quantitative Measurement of Neutron Induced Activity 
In Biomedical Applications, Physics. Guildford, University of Surrey. Ph.D.
Khan, F. M. (1994). The Physics of Radiation Therapy. London, Williams and Wilkins.
Rrane, K. S. (1988). Introductory Nuclear Physics. Wiley.
Ma, A., Awotwi-Pratt, J., Alghamdi, A., Alfuraih, A., et al. (2008). "Monte Carlo study of 
photoneutron production in the Varian Clinac 2100C linac." Journal of 
Radioanalvtical and Nuclear Chemistry 276(1): 119-123.
McCall, R. C., SWANSON, W. P. (1979). Neutron Sources and Their Characteristics. Conf. 
on Neutrons from Electron Medical Accelerators ,NBS Special Publication 554
NBS.
McGinley, P. H, and Landry, J. C. (1989). "Neutron Contamination of X-Rray-Beams
Produced by the Varian Clinac-1800." Physics in Medicine and Biology 34(6): 777- 
783.
NCRP (1984). Neutron contamination from medical electron accelerators : recommendations 
of the National Council on Radiation Protection and Measurements. Bethesda, Md., 
National Council on Radiation Protection and Measurements.
Petti, P. and Lennox, A. (1994). "Hadronic Radiotherapy." Annual Review of Nuclear and 
Particle Science 44: 155-197.
41
Photonuclear production in Medical linear Accelerators
Podgorsak, E. B. (2006). Radiation Physics for Medical Physicists. Berlin, Springer.
Rawlinson, J. A., Islam, M. IC. and Galbraith, D. M. (2002). "Dose to radiation therapists 
from activation at high-energy accelerators used for conventional and intensity- 
modulated radiation therapy." Medical Physics 29(4): 598-608.
Swanson, W. P. (1979). "Improved calculation of neutron yields released by electrons 
incident on selected materials." Health Physics 37: 347-358.
Tosi, G., Torresin, A., Agosteo, S., Para, A. R, et al. (1991). "Neutron Measurements around 
Medical Electron-Accelerators by Active and Passive Detection Techniques." Medical 
Physics 18(1): 54-60.
Zanini, A., Durisi, E., Fasolo, F., Ongaro, C., et al. (2004). "Monte Carlo simulation of the 
photoneutron field in linac radiotherapy treatments with different collimation 
systems." Physics in Medicine and Biology 49(4): 571-582.
42
Neutt'on Dose Measurements
Chapter 4 : Neutron Dose Measurements
Neutron monitoring in the vicinity of a high energy medical linac ( > 10MV) is essential 
radiation protection requirement during commissioning to determine neutron leakage from 
linac treatment head and to asses neutron dose equivalent inside the treatment room.
include dose-meter such as the ASP-NRD neutron survey meter, passive detectors include the 
use of activation foils and bubble detectors.
4.1 Estimation of Dose Equivalent in the Linac Maze
Neutrons fluence-to-dose-equivalent conversion coefficients had been evaluated rigorously 
over the past forty years or so, various conversion coefficients had been proposed using 
different evaluation methods, with diverse simulation codes, in different phantoms and 
geometries (ICRP 1964; NCRP 1971; NCRP 1991; ICRP 1996; McDonald 1998). Figure 4.1. 
shows a compilation of fluence-to-dose-equivalent conversion coefficients for neutrons as a 
function of neutron energy from some published literature, for neutrons energies below 20 
MeV. The discrepancies between the plotted conversion coefficient data sets are small ( on 
the order of 10 to 30 % ), and can be ignored when compared to the uncertainties in the 
estimated risks from exposures to neutrons (McDonald 1998) and hence most conversion 
coefficients can be used directly(NCRP 2005). In this work the NCRP No. 79(NCRP 1984) 
fluence-to-dose-equivalent conversion coefficient was employed :
Monitoring for neutrons can be done with either active or passive detectors. Active detectors
77 = (4.1)
where (p is the neutron fluence and E is the average neutron energy before passing 
through the linac head.
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Figure 4. 1 Neutron fluence to dose-equivalent conversion coefficients versus neutron 
energy (McDonald 1998)
4.1.1 Neutron Dose Equivalent at the Linac Maze Entrance
Evaluation of the neutron dose equivalent at the maze outer entrance of a high energy 
medical linac is required for the maze design in order to shield from neutrons. Different 
analytical methods had been developed to estimate the neutron dose-equivalent employing 
the concept of the tenth-value layer (TVL) which is the distance required for thermal neutron 
fluence to decrease 10-fold through mazes and large ducts (NCRP 2005). Two of the 
techniques are discussed below.
4.1.2 Kersey’s Method
Kersey’s method(Kersey 1979) was one of the first developed methods for evaluating neutron 
dose at the maze outer entrance. This estimation assumes that neutrons are produced at the 
isocentre of the accelerator, it evaluates the neutron dose equivalent at the outside maze 
entrance per absorbed dose of photons at the isocentre as(NCRP 2005):
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1 0 * )
where, as illustrated in figure 4.2.;
Ho is the total neutron dose equivalent at a distance do (1.41 m) from the target per absorbed 
dose of photons at the isocentre, it had been tabulated in literature for different linac systems 
and energies(McGinley 2002; Followill 2003)
So/Si is the ratio of the inner maze entrance cross sectional area to the cross-sectional areas 
along the maze
di is the distance from the isocentre to the point at the maze entrance where it just becomes 
visible.
is the distance from dj to the maze exit.
Figure 4. 2 Linac room layout for neutron dose equivalent calculation, not to scale(NCRP 
2005)
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Kersey’s method was found to be inconsistent with measurements of neutron dose 
equivalent when evaluated by McGinley and Butker (McGinley 1991) for various linac 
models with different range of energies. Therefore a modification was suggested by 
McGinley and Huffman(McGinley 2000) which was further modified by Wu and McGinley 
(Wu 2003) to accommodate for nonstandard linac width or length. Their modification 
incorporates the tenth-value layer (TVL) and is:
H,(n,D) =  2.4 x 10-15 cpA - m
Where cpA the neutron fluence per unit absorbed dose of photons at isocentre and TVD is the 
tenth-value distance, VD =  2.06^/S^ .
4.2 Dose Survey
4.2.1 The Neutron Survey M eter
The following description of the Neutron Survey Meter is summarised from NCRP 151.
The neutron survey meter used for dose monitoring in this work consists of two main 
complementary modules; the Neutron Radiation Detector (NRD) sphere, and the ASP-1 
analogue counting instrument. The NRD is a 22.9 cm diameter, cadmium loaded, 
polyethylene sphere, housing a boron triflouride (BF3) proportional tube in the centre. The 
polyethylene moderates fast and epithermal neutrons, in order for neutrons to be detected 
with greater efficiency by the BF3 tube. A spherical geometry is used so that the moderator 
materials present a uniform distribution to any direction of the incident radiation field. 
According to the manufacturer, this detector has a dead time of 10 ps (nominal), and has a 
response that closely follows a theoretical dose equivalent for neutrons over the energy range 
from 0.0025 eV to -10 MeV. The dose-equivalent range is 1 to 100 mSv I f 1. The instrument 
provides gamma rejection up to -5  Gy h-1 .
The BF3 proportional counter allows the detection of thermal neutrons through ionisation 
pulses induced by the neutron capture reactions 10B (n,a):
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10B + Jn 3Li +  f a  Q-value = 2.792 MeV (ground state)
10B + Jn -» 3Li* + fa  Q-value = 2.310 MeV (excited state)
The ASP-1 NRD neutron survey meter was calibrated at the National Physical Laboratory, 
Teddington, using an americium-beryllium neutron source with an average energy En = 
4.5MeV at three dose rates: O.ISpSvh"1, l.OpSvh"1, and 5.0p.Svh4 . The dose rate from another 
reference source was then measured to double-check the detector output.
4.2.2 Pulse Pileup within the Neutron Survey Meter
Medical linear accelerators produce pulsed electrons at repetition rates in the range of 
100-400 pulses per second with pulse widths of 1-10 ps, which may interfere with 
electronics within the detector. Discriminator circuits within the instrument are made to reject 
photons from steady fields, however, at pulsed field; this can overwhelm the detector 
electronics. As such, it may register the repetition rate of the linac leading to an over-register 
of the actual neutron dose when surveying close to the accelerator. For pulsed radiation, and
if the dead time is shorter than the pulse width, the corrected number of counts is related to
the measured number of counts by the following formula (NCRP 151):
where;
Ccorr is the corrected count. 
Cn is the measured count.
To is the dead time.
Tp is the pulse width.
Pr is the pulse repletion rate
C, C, (4.5)corr
If To > Tp Then:
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Ccorr = c „ - p r Inc rr
(4.6)
For moderated detectors such as the NRD Neutron Survey Meter, the effective dead time is 
determined by the moderation time and not the pulse width and therefore the moderation time 
is used instead of the pulse width.
Finally, due to the low neutron dose-equivalent rates present around most well-shielded 
radiotherapy units, it is recommended to use the Neutron Survey Meter in integrate mode and 
over a period of time.
4.3 Neutron Dose Measurements
The neutron dose survey was carried out primarily in the maze, treatment room, and patient 
waiting area for a radiotherapy treatment room, which houses a Varian Clinac 2100C 
operating at 15MV. Irradiation was with the jaws opened to a 20cm x 20cm beam field at 
400 Monitor Units (MU), the equivalent of 4Gy absorbed dose, at a treatment head angle of 
0°. Measurements were taken in ‘integrate mode’ at the maze entrance to compare with the 
calculated Kersey method at 3 additional points in the linac maze, figure 4.5.
Figure 4. 3 Schematic diagram o f the LA 3 linac treatment room and the neutron 
measurement points
4
t l  3 1 /2  1
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4.3.1 Results and discussion
Figure 4.4. shows the dose equivalent in Sv/Gy photon dose obtained from the NRD neutron 
survey meter. In the linac inside-entrance maze, point 1 in figure 4.3, the dose equivalent 
from the NRD survey meter was 8.3 pSv/Gy. At the outer-entrance of the maze, point 4 in 
figure 4.3 the dose equivalent obtained with NRD was 0.04 pSv/Gy. It is generally 
acknowledged that the total uncertainties associated with measuring absorbed dose with 
moderated neutron survey meters including that of the calibration source strength and the 
neutron fluence to absorbed dose conversion coefficients is approximately 20% (McGinley 
1976).
To estimate the neutron dose equivalent at the outer maze entrance using Kersey’s method, 
the highest value for Ho in equation 4.2. for 15MV linac was obtained from Appendix B in 
NCRP 151 (NCRP 2005). Calculation of the dose equivalent at the outer-entrance of the linac 
maze using Kersey’s method gave 0.47 pSv/Gy, when utilising the Wu and McGinley 
modification to the Kersey method(Wu 2003) equation 4.3, the neutron dose equivalent was 
estimated to be 0.085 pSv/Gy which is 52% greater than NRD survey meter value.
The layout of the linac treatment rooms in the Royal Surrey County Hospital where the 
measurements took place is constructed so that two linac rooms (LA3 and LA4) mirror each 
other, figure 4.5. In order to estimate dose due to neutrons to staff and to the general public in 
the waiting area neutron survey was performed in few extra locations; in the linac control 
room where cable ducts go through the wall into the treatment room (point 5) in the 
ventilation ducts on the ceiling of each outer maze entrance (point 6) at a point equidistant 
from both outer maze entrances with both linacs operating at the same time (point 7), and at 
the patient waiting area (point 8). The results of the measurements are tabulated in table 4.1. 
The highest dose equivalent (0.033 pSv Gy'1) was observed when operating both linacs 
simultaneously, point 7 in table 4.1. For a maximum patient load of 40 patients per day and 
an average of 4 Gy per treatment and based on 5 working days per week, the neutron dose 
equivalent per week become 26.4 pSv, this is 3.8 times lower than the shielding design goal 
of 0.1 mSv per week for controlled areas recommended by NCRP 151. As for uncontrolled 
areas, the NCRP shielding design goal is 0.02 mSv per week and the maximum neutron dose 
equivalent per week at the (uncontrolled) patient waiting area (point 8) given the same
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workload was found to be 6.4 pSv per week «  3 times less than the NCRP 
recommendations.
Both the cable access ducts (point 5) and the ventilation ducts (point 6) are smaller than the 
size of the NRD meter, and “as with any radiation detector a correct response is obtained only 
when the radiation field irradiates the entire detector (i.e., the size of the radiation field is 
larger than the size of the detector). If the size of the radiation field is smaller than the size of 
the detector, a reduced response will be obtained, as is the case of measurements through 
gaps or small holes in the shield”(NCRP 2005). The highest dose was observed when 
operating both linacs simultaneously, point 7 in table 4.1.
0
<8
§
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Position
Figure 4. 4 Neutron dose equivalent across the linac maze entrance measured using the 
neutron survey meter with BF^Measurements points position corresponds to points in figure 
4.5)
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Table 4.1 Dose-equivalent outside ti'eatment rooms
Point Dose Equivalent 
jiSv/Gy
LA3 LA4
5 0.006 0.008
6 0.004 0.007
7 0.033
8 0.008
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points outside the room.
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Chapter 5 : Neutron Contamination in the Vicinity of a Medical 
Linac
5.1 Introduction
Neutrons are uncharged particles and hence generally detected indirectly via nuclear induced 
reactions that result in prompt charged particles such as photons, protons, alpha and others. 
Because the cross section of neutrons in most materials is a strong function of the neutron 
energy, detection of neutron can fall into two broad categories depending on their energy, 
thermal neutron detection ( radiative capture) and detection of fast neutrons (moderation, fast 
neutron induced reaction, elastic scattering).
5.2 Thermal Neutron Detection
In choosing a neutron detector material one has to consider the nuclear reaction cross section 
and the associated particle Q-value, a large cross section is desirable in order to produce a 
practical compact detector while a higher Q-value will enable discrimination against gamma 
rays which commonly accompany neutron source. Other factors to be considered include the 
natural abundance and the cost of the detector material. The main reactions involved in 
thermal neutron reactions include the 10B (n, a), 3He (n, p) and 6Li (n, a) briefly discussed in 
the following section.
5.2.1 Boron reaction 10 B (n, a)
The most used reaction for the detection of thermal neutrons, the 10 B (n, a) reaction has a 
thermal cross section of 3840 barn, which is a 1 /v absorber i.e. its cross section decreases 
with the inverse of the velocity of the neutron. The reaction can be expressed as:
10B +  Jn -» -^ Li +  Q-value = 2.792 MeV (ground state)
+  Jn 3L1* + 2a  Q-value = 2.310 MeV (excited state)
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94% of the all reactions lead to the ?Li nucleus in excited state which reduces to the ground 
state by the emission of a 0.482 MeV gamma ray. Proportional gas detectors Boron 
trifluoride (BF3 ) is the most common employed gas in these propotional gas detector.
5.2.2 Helium reaction 3He (n, p)
The He (n, p) reaction has a high thermal neutron cross section of 5330 bam, and also 
exhibits 1/v characteristics. The reaction can be represented as:
zHe + Jn -> fH + fp Q-value = 0.764 MeV
With the high cross section, 3He detectors have a higher efficiency than 10B based detectors, 
however their high cost limit their wide use.
5.2.3 Lithium reaction 6Li (n, a)
The thermal neutron cross section for the 6Li (n, a) reaction is 940 barns but the high Q-value 
makes it a popular reaction for thermal neutron detection. The reaction can be written as:
|L i +  Jn 2H + f a  Q-value = 4.78 MeV
The cross section versus neutron energy, which shows the 1/v dependence for the three above 
reactions, is shown in figure 5.1.
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Figure 5. 1 Cross section versus neutron energy for He-3, B-10, and Li-6 reactions, from  
ENDF/B-6.1. plotted using MCNPX.
5.4 Fast Neutron Detection
The same reactions employed in thermal neutron detection can, in principle, be used to detect 
fast neutrons, however and due to the 1 /v properties, the cross section drops with increasing 
energy which makes it less probable for a fast neutron to interact with such detector. In order 
for these reactions to be used for fast neutrons detection, a moderator can be used to slow 
down the neutrons before reaching the detector. Other detection schemes are also employed 
for fast neutrons.
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5.4.1 Moderation-Based Detection
Fast neutrons can be detected by applying a neutron moderator to slow neutrons down before 
detection. Fast neutrons can lose a fraction of their initial kinetic energy before registering in 
the detector as a low energy neutron for which the detector efficiency is generally high. 
Moderator thickness is an important factor to be considered, while a thicker moderator, in 
theoiy, will increase the detector efficiency by slowing-down neutrons to the most probable 
detection energy by the time they reach the detector material, increasing the moderator 
thickness may also leads to more neutrons being absorbed by the moderator materials before 
registering at the detector. As a result, the efficiency of a moderated detector when used with 
a monoenergetic fast neutron source will exhibit a maximum at an optimum thickness before 
decreasing. This optimum thickness ranges from a few centimetres for lceV energy, up to 
several tens of centimetres for neutrons in the MeV energy range. A preferred moderator 
would be made of hydrogenous material such as polyethylene or paraffm(Knoll 2000).
5.4.2 Direct Fast Neutron-Induced Reactions
The moderation-based detectors rely on the slowing down of a fast neutron in the moderator 
material before it is finally detected as a thermal neutron. This indirect process has two 
downsides; first, it eliminates all information about the original energy of the fast neutron and 
secondly, due to the inherent lag time of fast neutron collisions with the moderator material 
before registering an event at the detector, it cannot provide a fast detection signal required 
in many neutron detection applications (Knoll 2000). A process by which fast neutrons 
interact directly with a suitable material shall eliminate these two problems.
Both of the He (n, p) and Li (n, a) reactions employed in thermal neutron detection and 
discussed above can be utilised in fast neutron detection. Figure 5.2. shows the cross section 
for the fast neutron region for both reactions, with a clear resonance for the 6Li (n, a) 
reaction at about 250 lceV.
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Figure 5. 2 The He (n,p) and Li (n,a )  fast neutron cross section, from ENDF/B-6.L plotted 
using MCNPX.
These detectors can be used to detect the presence of fast neutrons by arranging to count all 
or a fraction of the neutron-induced reactions in the detector.
5.4.3 Elastic Scattering Based Detection
For fast neutron detection, the most common method is based on the elastic scattering of 
neutrons by light nuclei. In elastic scattering, some portion of the neutron kinetic energy is 
transferred to the target nucleus to produce a recoil nucleus. The most popular* target is 
hydrogen and the resulting recoil nucleus is called recoil proton which is relatively easy to 
detect and hence forms the basis for most of fast neutron detectors.
To study the kinematics of neutron elastic scattering, it is necessary to consider the collision
with both the laboratory frame of reference, as well as the centre-of-mass frame of reference
(Beckurts 1964), the collision is illustrated in figure 5.3.
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where for the lab system:
vi = the velocity of the neutron before the collision 
v2 = the velocity of the neutron after the collision 
vm = the velocity of the centre of mass 
6 = the scattering angle 
while for the centre-of-mass system: 
vi - vm = the velocity of the neutron before the collision 
va = the velocity of the neutron after the collision 
\|/ = the scattering angle
The relation between v a , v m and v 2 as can be inferred from figure 5.4
Centre — of — mass Lab system
Scattered neutron Scattered neutron
///
/
Incoming neutron
Target nucleus
\
Recoil nucleus $
V22= va2 + Vm + 2va vm cos y/
Figure 5. 3 Neutron elastic scattering kinematics
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Figure 5. 4 the relationship between va, vm and V2 in figure 5.3
From momentum conservation, the velocity of the centre-of-mass is:
= (5*1)
m A + l
In the centre-of-mass, the velocity of the neutron before the collision is :
^ (5.2)
V 1 ' v"' = 3TT 1
From conservation of momentum and energy in the centre of mass, it follows that the post -  
collision velocities of the neutron and of the nucleus must be the same as the velocities before 
the collision. Thus:
A (5.3)
Va = ITT Vl
1Since energy (E = -  m v 2), substituting energy for velocity in equation 5.1, the energy of the
(5.4)
neutron after collision in the lab system (E2):
A2 + 2A cos if) + 1 
2 “  El (A + l ) 2
The scattering angle in the lab system is:
Acosib + l  ^Cos e =     p  2)7
f  A2 +  2A cos if) + 1
Combining these, then the energy of the neutron after collision becomes:
4A  _ (5.6)
E2 = (T + 4 ) 2 Ccos 9)E i
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The maximum energy loss occurs in a head-on collision ( 6 = 180, since cos 180 = -1 ), 
which results in the maximum possible recoil energy:
4A (5-7)
E 2  — ~7Z R l2 (1 + A )2 1
From equation 5.7. it is clear that the maximum fractional energy transfer decreases 
proportionally as the target nucleus mass increase which makes light nuclei, especially 
hydrogen, an obvious choice in recoil detectors.
5.5 Methods of Neutron Surveys around a Medical Linac
Neutron measurements in a mixed radiation field such as the vicinity of a high energy 
medical linac face the difficulty of pulse discrimination, due to the large photon to neutron 
ratio; photons interact directly with the detector causing pulse pile up. Another difficulty in 
detecting neutrons around the linac is the short pulse nature in which the linac generates the 
initial electrons and consequently the photoneutrons, i.e. linac repetition rate. To overcome 
these problems, passive i.e. activation detectors, should be the preferred choice for neutron 
measurements around a medical linac.
5.5.1 Activation
Activation detectors are widely used to characterise photoneutrons from a medical linac, they 
can be used alone to detect fast neutrons, examples include aluminium (Gur 1978) and 
phosphorus (Bading 1982) or in combination with a moderator for thermal neutron detection 
like gold (Palta 1984) or indium (McGinley 1976; Ipe 2006). These are usually shaped into 
thin, disk-shaped foils with a surface area in the range 0.1-10 cm2 (Beckurts 1964) and hence 
termed activation foils.
Activation foils are based on the principle of neutron activation, whereby certain materials, 
when irradiated by neutrons, become radioactive through different interaction mechanisms. 
Information about the number of neutrons as well as their energy distribution can be inferred 
from measurements of the resulting activity through appropriate detectors.
Activation foils have the advantage of their low cost, insensitivity to gamma radiation and 
small size which makes them convenient to use and the fact that they do not require special
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electronic equipment during irradiation. The main disadvantages, however, come from the 
fact that they require separate counting and analysis using complex equipment assemblies.
In choosing materials for activation, the most significant considerations are: high (n,y) cross 
section , a suitable half-life i.e. neither too short nor too long for the nuclide produced, high 
purity of the material, the physical properties of the material (preferably metallic foils or 
wires) (Knoll 2000) and its availability.
In this work both indium and aluminium were used for the following reasons:
Indium is readily available, has a high cross section for thermal neutron absorption and with a 
half life of 54 minutes was ideal for counting on site at the hospital.
Aluminium was used for two main reasons; availability; it is readily available as commercial 
baking foil. The baking foil, available in shops, is adequate for activation studies having 
purity above 99%, and it is also easy to shape for the intended measurements. This means for 
the same mass of foil, less self-absorption/flux perturbation will occur as the foil covers a 
larger area. Table 5.1. shows some useful activation materials, highlighted are aluminium and 
indium.
Table 5.1 Activation detectors and their properties (IAEA 1974; Baum 2002)
Nuclide Reaction Product half - 
life
Effective
threshold
MeV
Cross section 
(bams)
(vo=2200 m/sec)
Decay
Radiation
(MeV)
2,A1 (n, y )28Al 2.25 min (thermal) 0.232 y: 1.779 
P-:2.86
^ A 1 (n,p) Mg 9.45 min 4.5 y: 0.843, 1.014 
(3-: 1.75,1.59
27A1 (n,a)24Na 14.95 hour 7.1 y: 1.369, 2.754 
P-: 1.391
ll3In (n,y)n4mIn 50 d (thermal) 7.8 y : 0.558,0.725
115In (n,y)ll6mIn 54 min (thermal) 161 y: 1.293,1.097, 
2.12,.. 
p-: 1.00, 
0.87,0.60
Au (n!y)™AU 2.7 d (thermal) 98.8 y:0.412
(3-:0.961
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5.5.1.1 The Activation Equation
For a target nucleus \X  undergoing radiative capture, the residual nucleus usually decays 
according to
j x  + l n ^ A+$ X  + f } -  + Y
(5.8)
Figure 5.5 shows the change of activity for an activation foil during irradiation with a beam 
of mono-energetic neutrons and subsequent removal for counting. The time period from 0 to 
to represents the irradiation time, the time period to to t] is the waiting time and the time 
period tj to is the counting time. If left long enough the activity would plateau and reach a 
constant value where decay is equal to the rate of production (to).
A(f)
A oo 
Ao
Figure 5. 5Activity o f  an activation fo il after insertion into a constant neutron flux at time 
0 and removal at time = to (Knoll 2000)
Through the period ti 0 —» to , the reaction rate R can be given as:
r  =  <PcrNtV (5.9)
Where Nt is the number of target nuclei per unit volume, V is the foil volume, 0  is neutron 
flux and a is the cross section of interaction. For a foil of mass M, Nt is defined as:
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N t =  (5-10)Aw
Where Na is Avogadro’s number and Aw is atomic weight.
As the foil is irradiated, the material will be decaying at a rate defined by its decay constant A, 
the rate of decay is given by XNt . The rate of change in the total number of radioactive nuclei 
is given by the difference between the reaction rate R and the rate of decay:
Where N0 is the number of the produced nuclei. The disintegration rate D as a function of the 
irradiation time L (between 0 and to) is:
D = 0 a N t
1 -  e ~ u t \  (5.12)
Factoring in the counting time tc, the waiting time tw the flux perturbation F  and the 
efficiency of the detector s:
]\f (1 (q~^-w — q~ (5.13)
D = £ <t>(T
AF
ReaiTanging for flux gives:
0  = __________________   (5-14)
s  0 f fN t ( l  — e " ;it0 (e " At“' — e~'1-(c»v+£c)
Because of the relatively short 54 minute half life of Indium (li6mIn), it is often used for the 
determination of low fluxes, it is also cheaper than gold, can be reused sooner after 
irradiation in comparison to gold, gold however can be read out long after irradiation and has 
only one naturally occurring isotope. The dominant gamma emissions for 116mIn are listed in 
table 5.2.
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Table 5.2Prominent gamma emissions o f  116mIn(Beckurts 1964)
Nuclide 1 1/2 Energy (MeV) Num ber of y rays
per decay
116mIn 54 min 2X2 016
1.76 0.02
1.51 0.07
1.29 0.84
1.10 0.61
0.83 0.14
0.41 0.30
0.14 0.06
5.6 Initial Estimation of Fluence
McCall et al studied the neutron field intensity and spectral distributions(McCall 1978). The 
work takes into account the initial 'raw' spectrum and modifying effects of photon shielding 
materials and concrete room shielding, using both experimental and Monte Carlo simulation 
results, “a linear' relationship holds very well” . The formula can be simplified to:
0  total =  <t>dir +  <t>s + 0t/i =  ( ^ 2 )  +  + (5.15)
where :
<f)dir = direct neutron fluence (neutrons incident directly from the source)
<j)s = scattered neutron fluence from the concrete room walls 
<f)th = thermal neutron fluence
a = transmission factor for neutrons that penetrate the linac head shielding (1 for lead & 0.85 
for tungsten).
S  = treatment room surface area (cm2)
0  = neutron source strength per x-ray dose unit in neutron per second.
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d -  distance from target to point where fluence is evaluated.
Using this formula an initial estimation of the neutron flux expected at the position of the 
patient could be made. To determine 0  values a, S, Q & d  had to first be determined. To 
establish a, the compoimd ratio of lead and tungsten in the collimation is required. However 
it is generally believed that the majority element in the compound is tungsten. Thus a rough 
estimation has been made for the value of a. The compound mix has been estimated as 80% 
tungsten and 20% lead. To determine S, the full set of building plans have been investigated 
to work out the surface area of the treatment room.
The neutron source strength Q values had been studied and are tabulated in 
literature(McGinley 2002; Followill 2003) .Applying the McCall formula, to the linac room 
in this work to estimate the total neutron fluence was found to be 1 x 107 neutrons per cm2
5.7 Measurements of Neutron Fluence 
5.7.X Correction Factors
When performing neutron measurements with activation foils it is assumed that the neutron 
field incident on the foil is the same as that which was present before the foil was introduced. 
In reality, each foil perturbs the neutron field (Beckuits 1964) and in order to obtain 
reasonable accurate results for both thermal and epithermal neutrons certain correction 
factors have to be applied. The necessary correction due to flux perturbation are (1) self­
shielding effects, (2) flux depression, correction also may be required for the foil edge effect.
5.7.1.1 Flux Perturbation
Introducing an activation foil into a thermal neutron flux leads to self-shielding in the foil and 
a flux depression in the medium surrounding it (IAEA 1970)
In figure 5.6 (po is the flux before the introduction of the foil ,<ps is the flux at the surface of 
the foil, and <p is the mean flux in the foil. Perturbation can be defined by the flux 
perturbation factor Fj where:
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Fi can be further broken into two components, the coefficient of self-shielding G, and the 
coefficient of flux depression H.
Figure 5. 6 Schematic diagram o f flux perturbation due to the insertion o f an activation foil 
into the medium(IAEA 1970)
5.7.1.1.1 The Self-Shielding Factor, G
The self-shielding effect is due to the fact that the outer layer of a foil placed in a neutron flux 
reduces the flux to the interior of the foil thus the average flux within the foil is less than that 
at the surface. The coefficient of the self-shielding of a foil G is the ratio of the mean neutron 
flux in the foil <p to the flux at the surface <ps
G = V_ (5-17)
<Ps
For a monoenergetic and an isotropic neutron source and for a foil of thickness r  in units of 
mean free path:
C(T) =  1 ~  M  (5.18)
(t  = Zt a )  where a = 2V/S is the mean cord of the sample and Zt is the macroscopic total 
cross-section of the sample, V and S are volume and surface area of the foil and E3 is the 
third order exponential integral:
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1 „ (5.19)
E3 (j) = -  [exp(-r) ( 1  -  r )  + r 2F 1 ( t ) ]
(5.20)
and:
£ i ( t )  =  +   - I n  r - y  (5.21)
y is a constant and = 0.577216 (IAEA 1970).
Helm (Helm 1963) had demonstrated that G(t) can be determined by setting:
I  — 2F 3 ( t)  _  (T _  T 2  . fp 9 2 2 8  — ln r )  fo r  t <  0 .1   ^ ^
2t 20 .5  f o r r > 3 . 5
values in the 0.1 < t  <3.5 had also been tabulated by the same author (Helm 1963).
5.7.1.1.2 The flux depression coefficient H
The flux depression effect is due the fact that absorption of neutrons within the foil leads to a 
reduced flux in the surrounding media hence the foil is regarded as a negative source of 
neutrons (IAEA 1970). The flux depression coefficient H  can be expressed as the ratio 
between the neutron flux at the surface (ps to the flux before introduction of the foil <p0 :
(5'23)H = —
<P o
Ritchie & Eldridge (Ritchie 1960) had theoretically and experimentally studied flux 
depression of a plane circular detector and had stated flux depression to be:
H =
I  + 9  £  c a G
(5.24)
1 +  g r
2 ,
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g  is a factor that depends on the foil dimensions and the neutron transport properties of the 
medium. Slcyrme had derived a formula for g  which was further modified by Ritchie & 
Eldridge (Ritchie 1960):
4  r  
9  n J t
3 n  r
1 _  16 Z -
(5.25)
where L is the diffusion length, r the foil radius , Xt is the mean free path of transport and K  
is the coefficient determined from curves drawn as a function of 2r/X for different values of
y-
For foils less than 10 mm thick g  can be approximated as(IAEA 1970):
g  £= 1 .05  r/>lt (5.26)
5.7.1.2 The Foil Edge Effect
The contribution of neutrons which enter through the edge of the foil to the activation of 
disk-shaped foils had been carefully studied by Hanna(Hanna 1963). For a disk-shaped foil of 
a thickness d  and a radius R placed in a monoenergetic isotropic neutron field, Hanna had 
developed the following approximation for the edge effect contribution e :
_ Ugd d ( n \ (5-27)
<p0{Ha dj nR*  '
where p a is the absorption coefficient. The correction due to the edge effect can be ignored 
in this study due to the fact that the radius of the foil is large compared to its thickness.
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5.8 Neutron Contamination Assessment around Medical Linac
5.8.1 Neutron Fluence Measurements
As discussed above and given their high neutron cross section, availability, natural 
abundance, short half life, and the fact that they could be machined into small, thin discs, it 
was decided that foil activation measurements would be made using indium and aluminium. 
The physical characterization of the foils employed in this work is highlighted in table 5.3.
Table 5.3 Physical characteristics o f  a foils used in this study
Foil Atomic Atomic Density Purity Mass (g) Thickness
Number Weight (g/cm3) (%) (mm)
Al 13 26.982 2.7 99.0 0.055 0.85
In 49 114.82 7.3 99.8 0.27 0.21
Measurements in this work were performed using a HARSHAW 76.2 mm x 76.2 mm Nal 
(TI), the main advantage of which was the high photon detection efficiency and the ease of 
transport compared to a HPGe semiconductor detector to the hospital where measurements 
and counting were conducted .The detector was connected to a CANBERRA multichannel 
(MCA) analyser running Genie 2000 gamma-ray analysis software figure 5.7 and figure 5.8. 
Measurements were taken at the isocentre of a Varian Clinac 2100C/D linac at the Royal 
Surrey County Hospital operating at 15 MV, Initial measurement with aluminium foils was 
taken at 2.5 cm intervals within a moderator consisting of block of 30 x 30 cm2 in area Bush 
Phantom (Bush 1946) tissue equivalent material to establish fluence depth distribution in the 
two filed size sets of interest to us : 0 x 0 cm2 (completely closed) and 20 x 20 cm2 
.Subsequent measurements were taken with indium foils placed within a moderator 
consisting of 5 cm thick slab of the tissue equivalent material.
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Figure 5. 7 Schematic diagram o f the detector set up for counting on site
Figure 5. 8 Medical linac in LA3 and detector setup on site
Measurements around the head of the linear accelerator were taken at two locations selected 
to verify the isotropic nature of the radiation and yield information regarding maximum 
neutron yield with respect to field size. Both locations were chosen to be approximately 100 
cm from the target, figure 5.9. shows a schematic diagram of the linac and the measurement 
points. Point 1 corresponded to the isocentre, (100cm SSD), point 2 was taken at the back of 
the linac head at a distance of approximately 100 cm from the target.
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foil position 2
+
Figure 5. 9 Schematic diagram o f the linac head and gantry with associated measurement 
locations
Measurements were repeated for both fully collimated 0 x 0  cm2 and open 20 x 20 cm2 field 
sizes for irradiation times of 60 s, at 400 MU where (IMU -  lcGy). At each location, 
measurement were also performed by sandwiching indium foils between two 0.75 mm thick 
cadmium sheets so that the ratio of thermal to epithermal neutrons within the beam could be 
derived. Measurements were also carried out at extra 4 points along the linac entrance, figure 
5.10. to study the fluence distribution across the linac maze entrance and for comparison 
with dose survey obtained with ASP-1 NRD mutton survey m eter,chapter 4.
Following the end of each irradiation, foils were transferred to the Nal(TI) detector situated 
in the control room. Each foil was counted over a 10-minute time period, with an average 
waiting time of about 60s which was noted each time.
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Figure 5. 1 0 Schematic diagram o f the LA 3 linac treatment room and the neutron 
measurement points
5.8.2 Results and Discussion
Figures 5.11. shows the variation in neutron fluence in the two collimation configurations 
with respect to depth in phantom using aluminium foil. Figure 5.12 shows measurements 
with open jaws using indium foils. As photoneutrons penetrate through the phantom 
moderation occur in the tissue equivalent material as it would do in a patient, with the highest 
thermal neutron fluence found at 5 cm depth.
Utilising the NCRP Report 79 (NCRP 1984) fluence to absorbed dose conversion 
factors equation 5.28, absorbed dose across phantom was calculated, the total absorbed dose 
range between 1.81 x 10"' to 2.1 x IO4 Gy per Gy of photon, figure 5.13.
„  _ 4  5 x l 0 10 (5.28)
n  — -----------------
V I
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Measurements made around the linac head at position 1 (isocentre) exhibited a 58% increase 
in neutron fluence as the jaws were opened, in contrast, the measurements made at position 2 
were almost identical, showing a 1% decrease in neutron fluence for the same exposure. 
Results at the isocentre showed that neutron production is greatest with the primary
• • • • 9collimation (the jaws) open, i.e. for a 20 x 20 cm field size maximum neutron fluence was 
measured experimentally as 6.4 ± 1.1 x 106 cm'2 with a cadmium ratio of 2.6 ± 1 .3  as 
opposed t o 3 . 7 ± l . l x l 0 6 cm"2 with a cadmium ratio of 2.3 ± 1.2 when jaws closed , figure 
5.15. Results show that with the primary jaws open the total number of neutrons as well as 
the thermal neutrons is higher compared to the case when the jaws are closed.
In this work results show that photoneutron production increases with the size of the radiation 
beam in an agreement with the MCNP4C calculations performed by Gamica-Garza (Garnica- 
Garza 2005) and the MCNPX calculations and bubble detectors measurements done by Kim 
et al. (Kim 2007). This is in contrast to the EGS4 modelling by Mao XS et al (Mao 1997) 
suggesting that the total neutron yield produced in the accelerator head is inversely 
proportional to the field size. This discrepancy can be related to the attenuation that neutrons 
undergo when the jaws are closed and further suggests that such neutron production arises 
from above the movable collimator. The variation between the magnitude of position 1 and 2 
thought to be due primarily to the non isotropic nature of the shielding design within the 
treatment head, whereby increased attenuation in the beam forward direction acts to further 
thermalise the beam.
As for the measurements across the maze, figure 5.14. shows the rapid drop in neutron 
fluence as moving out from isocenter, further measurement at the outer-entrance of the linac 
maze could not be conducted as no significant counts were obtained from the foils.
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Figure 5. 1 3 Neutron absorbed dose variation with depth in phantom for both open and 
closed jaws configuration
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FigureS. 1 4 Neutron fluence measurements across the linac maze entrance (figure 5.10)
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1-Open jaws 1-Closed jaws 2-Open jaws 2-Closedjaws
Figure 5. 1 5 Neutron fluence and Cd ratios at the two locations about the treatment head 
for 400MU at 15 MV (20 x 20 cm opened field  and 0 x 0 cm closed jaws)
5.8.3 Conclusion
Detection methods used for the measurement of neutrons particularly in those conditions 
where there is also a high photon fluence, is both difficult to achieve and can be limiting. 
Employing neutron activation techniques using small indium foils and subsequent gamma ray 
spectroscopy with a Nal(TI) detector counting full energy photopeak areas of the gamma-ray 
energies of interest, allowed calculation of neutron fluence for a variety of parameters around 
the medical linear accelerator head. These included foil activation measurements made 
directly within the primary photon beam of a 20 cm x  20 cm field to determine both 
maximum neutron fluence and also to compare those measurements made with the primary 
collimators closed for a given photon irradiation. Measurements show that for a 15 MeV 
Varian Clinac 2100C/D neutron yield increases with the size of the radiation field and that 
the maximum neutron fluence is achieved with a 20 x 20 field size. However, although there 
were differences in the Cd-ratio in the values obtained for open and closed jaws cases, the
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associated counting errors were too large to derive significant conclusions and more precise 
measurements need to be performed, one of which is spectroscopy measurements using 
lithium gadolinium borate (LGB) spectrometer (Williams 2004). Measurement with LGB 
took place concomitantly by another researcher at the same lianc. Chapter 6 will explore 
utilizing maximum neutron yields from high energy medical linacs for BNCT boosted photon 
therapy.
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Chapter 6 : Boron Neutron Capture Therapy with Medical Linear 
Accelerators
6.1 Introduction
Neutron capture therapy (NCT) is a technique designed to selectively direct high LET heavy charged 
particle radiation to tumours at cellular levels. Boron Neutron Capture Therapy (BNCT) is a binary 
radiation treatment method that uses specially combined pharmaceuticals to deliver Boron-10 to tumour 
cells which are then irradiated with thermal neutrons to produce high energy (1.47 MeV) a particles and 
recoiling lithium-7 nuclei (0.84 MeV) with a path length ,in soft tissues, of about 9 pm and 4.5 pm 
respectively.
The 10B thermal cross section is 3839 barn which is much greater than the capture cross sections of most 
nuclides naturally occurring in any significant quantity in the body (H, C, N, and O). Table 6.1 and 
figure 6.1. show cross section of !H, 14N along with some isotopes of interest in Neutron Capture 
Therapy (NCT)
Table 6.1 Thermal cross sections o f some isotopes o f interest for NCT (ENDF/B-VI2001)
Nuclide Interaction 2200 m/sec cross 
section(barns)
,4N (n,p) 1.81
3He (n,p) 5330
i°B (n,a) 3839
113Cd (n,Y) 20673
155Gd (n, Y) 60948
I57Gd (n,y) 255206
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Figure 6. 1 Cross section o f selected isotopes o f interest in NCT, from ENDF/B-VI. Plotted using 
MCNPX
The capture of a thermal neutron by 10B leads to a reaction which results in the emission of an alpha 
particle (a) and a lithium (7Li) ion:
4He +7Li +2.79 MeV (6.3%)
/
10B + nth -»nB* -» X 
\
4He + 7Li * +2.31 MeV (93.7%)
i
7Li + y + 0.48 MeV
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As mentioned earlier these are both high linear energy transfer (LET) particles with short ranges (~10 
pm) in tissue, and therefore highly effective in damaging the DNA of cells. The short range of these 
particles ensures that tumour cells can be killed very selectively if the boron is localised in the target 
cells or on the surface of the cells. The cellular damage produced by these short range, high LET 
ionizing particles depends much less on the presence of oxygen in the cancerous cells than is the case 
with other ionizing radiations in therapy, such as x rays, gamma rays, and electrons. It is common for a 
rapidly proliferating tumour as in the case with Glioblastoma Multiforme (GBM), the target for most of 
ongoing BNCT trials, to outgrow its blood supply, so that some areas receive less oxygen than normal 
tissues. As a result of this oxygen depletion, the tumour can become more resistant to the effects of 
conventional photon or electron radiation therapy. However, the effects of an oxygen reduction in 
tumour cells does not alter the tumours’ sensitivity to alpha particles and lithium ions radiation.
Another advantage of alpha particles and lithium ions is that they do not distinguish between the killing 
of dividing and non-dividing tumour cells (MIT BNCT Group 2000). Other forms of radiation treatment 
and chemotherapy are considered to be limited with respect to the eradication of viable, but inactive 
cells of the tumour.
BNCT takes advantage of the nuclear properties of boron 10B that have high neutron capture cross- 
section. Of the various other nuclides with relatively high neutron capture cross sections, clinical trials 
use 10B due to the following reasons;
1 it is not radioactive and is readily available, comprising 20 % of naturally occurring 
boron.
2 the particles emitted from the capture reaction, the alpha and Li particles, have a high 
LET.
3 The alpha and Li particles have a path length comparable with cell dimensions and this in 
theory limits the radiation effects to the cancerous cells were 10B is concentrated, allowing the 
sparing of normal tissue surrounding tumour site.
4 The chemical properties of 10B is such that it can be readily incorporated into an array of 
chemical structures (Spencer 1978).
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These characteristics are significant when aiming to destroy cancerous tissue within the body. Other 
capture agents, especially 155Gd and 157Gd, have higher cross sections than 10B, and have been studied 
extensively in their suitability for NCT (Tokuuye 2000).
6.2 History
It was Sweet, Farr and Brownell who first suggested BCNT as a novel treatment for brain tumours over 
50 years ago. The first BNCT clinical trial was initiated in 1951 and 1952 by a Boston team headed by 
Sweet at the Brookhaven National Laboratory (BNL) in the USA using thermal neutron beams to treat 
subjects with intracranial tumour's (Farr 1954). The results yielded from these studies provided no 
evidence of improved treatment over conventional modalities and adverse effects such as scalp necrosis 
were common among patients (Choi 1989). Simultaneously, trials conducted by Sweet and Brownell 
progressed at the Massachusetts Institute of Technology (MIT) (Godwin 1955). However, a similar lack 
of positive results inhibited the progress of these trials which were subsequently halted within the USA. 
The disappointing outcomes of these trials, which ended in 1961 were primarily attributable to (a) 
inadequate tumour specificity of the inorganic boron chemicals that had been used as capture agents, (b) 
insufficient tissue penetrating properties of the thermal neutron beams, and (c) high blood boron 
concentrations that resulted in excessive damage to normal brain vasculature and to the scalp (Barth 
2005).
In the late 1960s, Hatanka, working in Japan and following a 2-year fellowship in Sweet’s laboratory at 
the Massachusetts General Hospital introduced the applicability of BNCT for use in treating multiform 
gliablastomas using thermal neutron beams (Sweet 1983). However, in this procedure, Hatanaka 
surgically removed much of the tumour mass before administering the boron compound BSH (Na2 
B i2HhSH ) see figure 6.2. developed earlier as a boron delivery agent by Soloway at the Massachusetts 
General Hospital (Soloway 1967). Subsequently, BNCT was conducted 12-14 hours after boron 
delivery at several neutron reactors. By exposing scalp tissue and reflecting skull bone, Hatanaka 
eliminated the short penetration of thermal neutrons in tissue in order to protect the skin and improve 
neutron depth distribution (Hatanaka 1994).
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2: B SH
N a2
Figure 6. 2  BSH and BP A boron delivery agents in BNCT (Barth 2005)
In the late 1980s, Professor Yutaka Mishima from Kobe University in Japan studied a number of 
melanoma-seeking 10B compounds and he came up with 10B-para-boronophenylalanine (10B-BPA) as 
the most effective drug (Mishima 1989). He started clinical trials for patients with malignant melanoma 
using BPA in 1987(Nakagawa 2006).
In 1994 BNCT trials resumed in the United States, at the Massachusetts Institute of Technology (Busse 
2003) and at Brookhaven National Laboratory in New York (Diaz 2003). These trials used epithermal- 
neutron beam from the MIT Research Reactor and the Brookhaven Medical Research Reactor. (BPA) 
was used as the boron delivery agent. The Brookhaven trials were terminated in 1999. Clinical 
irradiations at MIT came to a halt few years later. Clinical Trials of BNCT for glioblastoma , cutaneous 
melanoma, and other tumours including head and neck and liver have also been ongoing at various 
centres over the world in the last 10 years these include clinical trials in Finland, Czech Republic, 
Sweden, the Netherlands, Argentina and Japan. Table 6.2. summarises recent and ongoing clinical 
trials in nuclear reactor facilities around the world.
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Table 6.2 Summary o f current or recently completed clinical trials o f BNCTfor the treatment o f  
glioblastoma (Barth 2005)
Facility Number of 
Patients
Drug Boron
concentration 
jig 10B/g
Estimated
Peak
Normal
Brain
Dose, Gy(w)
HTR,Musashi Institute 
of Technology, JRR, 
Kyoto University 
research reactor, Japan
> 200 (1968-present) BSH -20-30 15 Gy tuB 
component
High Flux Reactor, 
Petten, the Netherlands
26 (1997-present) BSH 30 8.6-11.4 Gy 10B 
component
LVR-15, Rez, Czech 
Republic
5 (2001-present) BSH -20-30 < 14.2
Brookhaven Medical 
Research reactor, 
Brookhaven, United 
States
53 (1994-1999) BPA 12-16 8.4-14.8
MITR-II, M67 MIT, 
United States
20 (1996-1999) BPA 10-12 8.7-16.4
MITR-II, FCB MIT, 
United States
6 (2001-present) BPA -15 Unpublished
Studsvik AB Sweden 30 (2001-present) BPA 24 (range, 15-34) 7.3-15.5
FiRl, Helsinki Finland 18 (1999-present) protocol 
P-01
BPA 12-15 8-13.5
FiRl, Helsinki Finland 3 (2001-present) protocol 
P-03
BPA 12-15 <8
6.3 Desirable Neutron beam for BNCT
The pattern of energy deposition on a microscopic scale is of principal importance in understanding the 
biological effects of BNCT. The poor penetration of thermal neutron beams makes them undesirable in 
BNCT applications. Initial research in BNCT used thermal neutrons beams for treating both surface and 
deep-seated tumours (Barth 2005). However, it was found that when curing deep-seated tumours, there 
were two important failures:
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i) Low fluence level at the tumours site
ii) Extensive damage to normal tissue
These effects can be attributed to the low mean free path length of thermal neutrons. In the early clinical 
trials of BNCT, a thermal beam had been combined with intra-operative techniques to overcome the 
poor penetrability of thermal neutrons (Fairchild 1966). For conventional BNCT treatment (non­
operative) it is necessary to have a higher initial energy to produce a better dose penetration and enable 
treatment of tumours located a few centimetres within brain tissue. However, this high energy beam has 
to be slowed down in order for thermal capture to occur at the tumour site. The process of reducing the 
energy of a neutron beam to the thermal region is referred to as moderation and the material used for this 
purpose is called a moderator. A good moderator reduces the speed of neutrons in a small number of 
collisions (inelastic scatting), but does not absorb them to any great extent. Water (natural and heavy 
water) is a common moderator in use. Epithermal neutrons can convert to thermal neutrons in tissues, 
resulting in an increase in the number of thermal neutrons delivered to deep-seated lesions figure 6.3. A 
typical neutron beam of choice for BNCT applications have neutron energies in the epithermal range (~1 
eV - ~ 30 keV) and is usually extracted from nuclear reactors. Such a beam needs to be moderated and 
filtered to adapt the neutron spectrum to that desired, however, some fast neutrons, thermal neutrons and 
y radiation are unavoidably present in the incident beam.
Most recently, a mixed thermal /epithermal beam had been used for intra-operative BNCT clinical trials 
in the Japan Research Reactor 4 research reactor (Yamamoto 2004).
The following parameters define the specification of an epithermal neutron beam for BNCT (IAEA 
2001):
(1) Epithermal Beam Intensity (defined as the flux of neutrons in the beam with energies between 0.5 eV 
and 10 keV) should ideally be at least 109 neutrons cm 'V 1. Less intense beams than this will require 
unreasonably long irradiation times (> 1 hour) which presents clinical difficulties in terms of prolonged 
immobilisation of the patient and may also be sub-optimal in terms of the boron drug biodistribution 
kinetics.
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Deptli in phantom (cm)
Figure 6. 3 neutron flux distribution with depth in phantom (IAEA 2001)
(2) Fast neutron flux component (taken as neutron flux with E >10 keV) should be as low as possible 
since this will lead to a non targeted normal tissue dose from hydrogen nuclei in tissue. Reducing the 
fast neutron component will always be to some extent a compromise with increasing the epithermal flux. 
The fast neutron component in most operating epithermal beams is typically in the range 2.5 -  13 x 10'13 
Gy cm'2 per epithermal neutron.
(3) The gamma ray component in the beam should be minimised. Some gamma rays are unavoidably 
generated in the patient (“induced gammas”) however the beam gamma KERMA component is typically 
between 1 — 13 x 10'13 Gy cm'2 per epithermal neutron and should be at the lower end of this range.
(4) Thermal flux in the incident beam will lead to increased superficial tissue dose and should therefore 
be minimised. A maximum thermal flux 5% of the epithermal flux has been suggested.
(5) Neutron current (the number of neutrons per second crossing a unit area normal to the direction of 
neutron flow) to flux ratio reflects the proportion of forward directed neutrons in the beam. A higher 
ratio results in minimal beam divergence and enables better dose delivery at depth. A suggested target 
for this parameter is 0.7.
(6) Maximum usable beam diameter is typically between 12 and 14 cm on exiting beams.
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6.4 Type of Cancer targeted
Clinical interest in BNCT has focused primarily on the treatment of high-grade gliomas and either 
cutaneous primaries or cerebral metastases of melanoma (Barth 2005). Most recently other forms of 
cancers have gained an interest for clinical BNCT these include head and neck (Rao M 2004) ,skin 
(Gonzalez SJ 2004) liver and lung cancer and recurrence breast cancer (Yanagie 2008). Liver cancer 
could be treated well by proton or heavy ions if the lesion is single. However if the lesion is multiple, the 
side effect of the charged particle therapy to the normal tissue is harmful. BNCT is a cell selective 
charged particle therapy of which selectivity is based on the drug accumulation. Therefore it may be 
possible to treat liver tumour with multiple lesions with BNCT (Matsumura 2005). Since the lung tissue 
contains a massive air component, the depth-dose curve is different from other solid organs which 
contain large amounts of water. The decrease of the neutron flux is less in the air than water. Therefore, 
lung cancer may be a good target for BNCT (Matsumura 2005).
6.5 Possible sources of neutrons
Facilities available for BNCT clinical trials are limited to research nuclear reactors at present. Few new 
dedicated research reactor projects are being initialised, while the majority are existing reactors modified 
for BNCT. Using such reactors for BNCT faces obstacles since reactors are not used solely for clinical 
trials and most frequently are used for other applications besides BNCT, Additionally, having to care for 
cancer patients, most at advanced if not terminal stages, away from hospital, where accessible and 
sometimes immediate emergency and resuscitation from specialised medical teams is necessitated and 
usually easy to deploy is a limitation in its own right. For these reasons, current research on BNCT 
neutron sources focuses on building new facilities at or near hospitals. A discussion of these sources is 
covered in the following sections.
I- Reactors
Most current research and clinical trials involving BNCT utilize general purpose research thermal 
reactors purposely modified and ultimately converted for such area of medical research. In order to get 
the appropriate neutron flux for treatment from a thermal reactor, fast neutrons from the core need to be 
moderated to more suitable neutrons of epithermal or thermal energy. This can be achieved by the 
means of spectrum shifting and/or filtering depending on the reactor aperture facility.
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Fast reactors had also been proposed for use in BNCT due to their low power and compact core, 
however the need for highly enriched uranium limits their future application for BNCT.
Dedicated and newly constructed reactors for BNCT is an appealing idea as they can be built around 
medical facilities and as they are purposely built they can carry prompt gamma neutron activation 
analysis (PGNAA) of boron in blood (Spyrou 1999) which is essential before delivering BNCT 
treatment. As the same issue with power reactors, public acceptance is a limitation especially since it 
involves installation in or near medical centres which are usually in highly populated neighbourhoods. 
Cost is another factor as estimates of experts indicate that the construction of a new BNCT facility costs 
about 5-7 million Euro, whereas adaptation of an old one costs 2-4 million Euro. (IAEA 2001)
Clinical research involving nuclear reactors is currently active across the globe at many specialised 
institutions. These consist of (1) MITR, USA (Harling O 2002); (2) The clinical reactor at Studsvik 
Medical AB, Sweden (Capala 2003); (3) FiR 1 reactor at Helsinki, Finland (Joensuu 2003); (4) R2-0 
High Flux Reactor at Petten, Netherlands (Barth 2005); (5) LVR-15 reactor at the NRI in Rez, Czech 
Republic(Burian J 2002); (6) Kyoto University Research reactor, Kumatori, Japan(Kobayashi 2000); (7) 
JRR4 at Japan Atomic Research Institute, Ibaraki, Japan (Yamamoto 2000); (8) the RA-6 CNEA reactor 
based in Bariloche, Argentina (Gonzalez 2004) and (9) the TAPIRO reactor at ENEA Casaccia Centre, 
Rome, Italy (IAEA 2001).
Reactors, however, require being close to medical centres with easy access for medical staff and patients 
which is not normally the case with reactors nowadays. Public acceptance is another obstacle along with 
the economics of transferring existing reactors for BNCT use and the extra cost of running such reactors. 
Licensing and medical liability are also other impediments for research reactors for BNCT
II- Accelerators
Various accelerator configurations have been proposed (for the production of neutrons) namely, (1) 
radio frequency quadrupole (RFQ) linacs, (2) tandem electrostatic linacs, (3) electrostatic quadrupole 
(ESQ) accelerators, and (4) RF focused drift tube linacs. The radiofrequency quadrapole (RFQ) 
accelerator is considered as the most promising method. The RFQ can be used to generate a high current 
of protons with an energy slightly higher than the threshold (1.88 MeV) for the 7Li (p,n) 7Be reaction. 
Accelerators suitable for BNCT would cost approximately three to four times the cost of a conventional 
high energy linear accelerator used routinely in hospitals around the world (Green 1998).
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High energy medical linear accelerators provide an alternative method of producing neutrons via 
photonuclear reactions in the target and other materials forming the collimator and flattening filters. An 
accelerator would be a useful BNCT neutron source in a hospital for several reasons. First, accelerators 
are much more acceptable to the public than reactors. Second, it generally involves fewer complications 
with respect to licensing, accountability and disposal of nuclear fuel. It can also be switched on and off. 
Resulting neutrons generally require less moderation than those from a reactor.
Neutron generation by a linear accelerator source may provide several advantages over systems based on 
uranium-fission neutrons from nuclear reactors: (1) the maximum neutron energy could be much more 
readily controlled by selection of the incident particle, its energy and the target material(Green 1998),
(2) the accelerator may be situated in close proximity to a hospital, (3) the irradiation could be started 
and stopped instantly for immediate access to the subject in case of an emergency, and (4) the neutron 
beam axis could be steered for more flexible planning of multidirectional neutron irradiations.
Ill- Californium
Californium-252 neutron sources are used for many applications in which compact and portable, neutron 
sources are required. The neutron spectrum emitted by Cf-252 has a Maxwellian energy distribution 
with an average energy of 2.1 MeV and most probable energy of — 0.7 MeV.While it might have a 
better acceptance compared with reactors however, the limited production, the tough acquisition and the 
half-life of 2.65 year of the isotope are the main limitations for its use. In addition, a source of the order 
of 1 g would be needed, which would be very difficult to obtain (IAEA 2001). Table (6.3) shows a 
comparison between the advantages and the disadvantages of possible BNCT neutron sources.
6.6 Initial Simulation for BNCT using linac
Monte Carlo radiation transport simulations are increasingly used to determine doses in complex 
geometries in mixed neutron- gamma fields. For most materials and neutron energies of interest in 
BNCT, neutron cross section data and the physics of the Monte Carlo codes are adequate to provide 
accurate calculations of dose. However, these Monte Carlo dose calculation depend for their accuracy on 
an accurate knowledge of geometry and isotopic make up of the material being simulated as well as an 
accurate knowledge of the initial neutron spectrum as an input to the calculations. Therefore it is 
essential that the results of Monte Carlo simulations are verified experimentally. Once evaluated for
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some standard energy and geometry for a given neutron beam facility more weight can be placed on 
computed results of the simulations of more complex problems.
In this simulation a modified head model originally described by Snyder (Snyder 1978) was used. The 
head model is represented by two nonconcentric ellipsoids containing homogenous regions of either 
bone or brain equivalent material(50%/50% by weight average of grey and white matter), the elemental 
compositions and densities of the skull and brain were taken from ICRU46 (ICRU 1992) table 6.5.
The first ellipsoid which defines the volume of the brain is represented by the equation:
( x )
2
+ M
2
+ f  2 )
w U .5 J
The skull is represented by the region between the surface described above and the noncncentric 
ellipsoid,
A tumour region of 1 cm3is assumed to be in the centre of the brain. Boron-10 is included in both 
normal brain and tumour tissues with concentrations of 10 and 30 pg/g, respectively. These 
concentrations correspond to the loading of BPA as a boron carrier currently used in clinical trials (Barth
2005). The addition of boron to the elemental composition should account for boron self-shielding 
effect (Ye 1999). The head model was placed at the isocentre of the treatment room, at 100 cm source- 
to-surface-distance SSD from source, figure 6.4. Since neutron spectra are affected strongly by bulk 
moderating materials, the concrete walls, floor and ceiling of the treatment room have been included in 
the simulation in order to take into account the backscattering effects.
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Treatment room Head phantom with added 
heavey water layer
Figure 6. 4  Modelled treatment room and head phantom with added surrounding layer o f heavy water
With a neutron point source, an attempt has been made to calculate the neutron flux at the tumour site, 
using an MCNPX built-in analytic function to generate a continuous probability density function for the 
source variable. The function used represents an isotropic Cf-252 Maxwell fission energy spectrum 
(f=—2) and gives a source probability p(E) of the form
p(E) = c jE e -E,a ( }
Where c is an MCNP normalisation constant, a is the effective temperature in MeV (default value: 
1.2895 MeV).
In neutron transport mode of the MCNPX 2.5.0 code (Pelowitz 2005), ten million histories of incident 
neutrons were run on a PC which has a CPU speed of 2.8GHz. Different runs of a plain head phantom 
with no surrounding layers of heavy water, and variant modifying layer of heavy water around the skull 
were simulated. Three configurations were considered with 1, 2 and 3 cm layers and 2 different SSD 
were examined namely at 50 and 100cm.
Figure 6.5. shows a comparison of the different results obtained with different configurations. Utilizing 
the measurements of neutron yield of linacs obtained by McCall (McCall 1987) the thermal neutron flux
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from a 18 MeV linac operating at a photon dose of 400 MU, obtained at the tumour site in the isocenter
of the brain at 100 cm SSD, was found to be 1.81 x 106 cm "/s. With the introduction of a 1 cm heavy 
water layer around the head phantom an increase of 29% of thermal neutron flux was achieved. A 2 cm 
heavy water layer produced 42% increase of thermal neutron flux at the tumour site, and a 45% increase 
was achieved when we applied a 3 cm heavy water layer, figure 6.5.
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Figure 6. 5  : Neutron flux at the tumour site from 18MV linac, SSD=100cm. The thermal neutron flux 
increased when adding heavy water layer around the head phantom
6.7 Zubal phantom head Simulation
Modelling using MCNPX 2.5.0 is conducted to calculate the photoneutron flux of an 18 MV Varian 
Clinac 2100C medical linac head, figure 6.6. with the aim of maximizing the thermal and epithermal 
neutron component in order to incorporate BNCT in medical linacs whilst minimizing the photon 
contribution from the primary beam.
As discussed in chapter 3, in medical linear accelerators (linacs) a beam of electrons is accelerated to 
high energy. It is then directed to strike at a high-Z target, usually made of tungsten alloy. The electrons 
are converted into a beam of bremsstrahlung photons. Since these photons are peaked in the forward 
direction, a flattening filter of medium-Z materials is used to flatten the beam profile so that the dose
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distributes evenly in the treatment field. To minimize the exposure of the normal tissues surrounding the 
tumour site, the photon beam is further shaped by a set of beam modifiers of high-Z materials before 
being delivered into the patient. The beam modifiers include two pairs of jaws and 80 pairs of multileaf 
collimator (MLC) leaves. The jaws move orthogonally to each other in an arc focused at the target. Each 
MLC leaf is doubly focused at the target and moves linearly. All these beam modifiers are capable of 
independent movements.
The Varian Clinac 2100C linac head is modelled in detail according to the manufacturer’s 
specifications and in a realistic treatment room configuration. It is made of elements specified in the 
manufacturer’s document, table 6.3. During the simulation the movable jaws and the Multi Leaf 
Collimators (MLCs) were closed to enable ( hypothetically) a higher photoneutron production from the 
high Z materials composing these.
Different configurations of the linac head were tested to maximize the exposure of high-Z materials to 
the photon beam. In this process simulation of the effect of the removal of the flattening filter, figure 
6.6. on increasing the photoneutron production in the linac head was performed .
Flattening filters are made of materials with medium atomic number (iron, copper). Studies so far had 
investigated removing of flattening filter in modern intensity modulated radiation therapy (IMRT) 
medical linacs in order to increase dose rate and lower out-of-field dose (Titt 2006). Monte Carlo 
simulation of the photoneutron production on the Varian Clinac 2100C with an initial electron beam of 
15MV indicated only ~ 1% of the total neutron production in the linac head (Ma 2008) was due to the 
flattening filter, calculation for the Siemens Primus linac (Pena 2005) ( 15MV photon beam ) with 
flattening filter made of steel showed that the flattening filter contribution to photoneutron production is 
negligible (0.41%).
In theory and because the number of neutrons generated in the linac head is directly dependent on 
photon fluence per incident electron, removing the flattening filter results in an increase in the photon 
fluence, hence the number of photoneutron interactions is increased and as a consequence more 
neutrons are generated per incident electron on the target.
However in measurements reported by Kry (Kry 2007) an approximate 20% decrease in neutron 
fluence per monitor unit was measured when the accelerator was operated in the flattening filter free 
mode than when it operated with a flattening filter, this can be reasoned to the fact that more photons are
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reaching and are registering in the monitor chamber when removing the flattening filter so the initial 
photon fluence produced at the target is consequently reduced. Hence, less photonuclear interactions 
take place and less neutron fluence is produced.
In our simulations, tallying for neutrons in a 10 cm water sphere at 100 cm SSD had shown an increase 
of neutron yield by 23 % over the whole spectrum when removing the flattening filter, figure 6.8, of this 
14.7% increase is in the thermal neutron component, 21.7% increase in the epithermal and 33.8 % in the 
fast neutron component.
Table 6.4. Neutron emission reaction channels fo r the nuclides considered in this work. These reaction 
cross sections are included in the calculations. Data are compiled from (IAEA 2000)
Threshold energy
nuclide (y, n) (y, 2n) (y, np) (y, 3n)
"27t o oo „ /„ „ZH 2.22 n/a n/a n/a
9Be 1.67* 20.56 18.92 31.24
12C 18.72 31.84 27.41 53.13
14n 10.55 30.62 12.50 46.24
160 15.66 28.89 22.96 52.06
56Fe 11.20 20.50 20.41 33.87
63Cu 10.85 19.74 16.72 31.45
184W 7.41 13.60 14.63 21.67
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Figure 6. 6 Modelled 18MeV linac and flattening filter
Further calculations using MCNPX 2.5.0 with a modified Zubal voxel-based anthropomorphic phantom 
head (Zubal 2003) figure 6.7. were undertaken with the same 18 MV Varian Clinac 2100C source . 
The elemental compositions and densities of the brain were taken from ICRU46 (International 
Commission on Radiation Units and Measurements. 1992).
A tumour region was assumed to be in the centre of the brain infiltrating the corpus callosum. Boron-10 
is included in both normal brain and tumour tissues with concentrations of 10 and 30 pg/g, respectively. 
These concentrations correspond to the loading of BPA as a boron carrier currently used in clinical 
trials. The voxel-based anthropomorphic phantom was placed at the isocentre of the treatment room.
Using MCNPX 2.5.0 tally F4 for (track length estimate of cell flux) neutrons and incorporating the 
measurements of neutron yield from linacs obtained by McCall (McCall 1987) we calculated the thermal 
neutron flux from an 18 MV linac operating at a photon dose of 400 Monitor Unit (MU), obtained at the 
tumour site in the centre of the brain at 100 cm SSD, to be 4.39 xlO7 neutron cm'2s'1. With 1 cm heavy 
water layer around the head an increase of 29% of thermal neutron flux was achieved. Whereas a 2 cm 
heavy water layer produced 42% increase of thermal neutron flux at the tumour site, and a 45% increase 
was achieved when we applied a 3 cm heavy water layer, figure 6.9.
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Figure 6. 7 Simulated Zubal head phantom and a cross section o f the original Zubal head phantom 
(Zubal 2003)
This will make it possible to use high energy clinical linacs in BNCT with a relatively high 
concentration o f  boron-10, by the introduction o f  heavy water layers which improve the thermal neutron 
flux at the tumour site. A combination o f  a high energy medical linac, a shorter SSD (<100 cm )and 
heavy water moderation layers will decrease the required boron-10 concentration to a level close to 
current clinical trials concentrations and will introduce linacs as convenient new modalities at a lower 
cost in BNCT treatment.
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6.8 Medical linac source vs reactor source for BNCT
Monte Carlo simulations were performed using MCNPX 2.5.0(Pelowitz 2005) A Snyder head model 
(Snyder WA 1978) described above, modified by Goorley et. al (Goorley 2002) was used with an 
added skin layer represented by :
Voxels in the phantom are of 8 mm at each side and differ by relative proportions of skin, bone and 
brain tissues., elemental composition are taken from ICRU46 (ICRU 1992) table 6.5.
Table 6.5 Densities and elemental composition o f cranium brain and skin as described by ICRU 46
Tissue Mass Elemental composition in mass percent
(g/cm3) __________________________________________________________
H C N O  Na Mg P S Cl K Ca 
Cranium 1.610 5.0 21.2 4.0 43.5 0.1 0.2 8.1 0.3 0 0 17.6
Brain 1.040 10.7 14.5 2.2 71.2 0.2 0 0.4 0.2 0.3 0.3 0
Skin 1.090 10.0 20.4 4.2 64.5 0.2 0 0.1 0.2 0.3 0.1 0
Simulations were repeated using two sources:
• A reactor epithermal neutron beam typically used for BNCT, at 15 cm source-to-surface-distance
(SSD). The spectrum comprises 10% thermal and 1% fast components (Goorley 2002).
® A photoneutron beam at 100 cm SSD, with energy spectrum of neutrons emitted from a
radiotherapy linac operating at 15 MV (Pena 2005)
Tally F4, a track length estimate of cell flux, was scored along the z axis of the head phantom. 
Normalized per source particle, it is given by
W * Tl/V ( 6 . 5 )
Where W = particle weight, V — volume (cm3) and 77 = track length (cm) = transit time * velocity.
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To maximize the thermal-to-fast-neutron ratio at the centre of the brain (where the tumour is assumed to 
be), the simulation with a medical linear accelerate source was repeated with moderators of different 
thicknesses placed between the source and the phantom. The moderator was composed of heavy water. 
To optimize the placement of the moderator, 3 configurations were considered:
A. a slab at SSD 10 cm;
B. a slab at SSD 90 cm;
C. an ellipsoid surrounding the phantom, effectively at zero SSD.
The moderator thickness was kept constant at 3 cm
Epithermal reactor beam with 10% thermal 1% fast component
I ......—■----- 1----- *---- "1—'---I—1--- 1........ ...1
1E-5 1E-3
neutron/cm  
cn to
S’ s* s? ?
E n e rg y  (MeV)
Figure 6. 1 0  Reactor neutron source (Goorley 2002): spectral variation o f neutrons with respect to 
depth in the head phantom.
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Figure 6. 1 1 Linac photoneutron source: spectral variation o f neutrons with respect to depth in the 
head phantom configuration. Head phantom without moderator.
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Figure 6. 1 2  Linac photoneutron source: spectral variation o f neutrons with respect to depth in the 
head phantom configuration. Heavy water moderator at 90 cm SSD.
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Figure 6. 1 3  Linac photoneutron source: spectral variation o f neutrons with respect to depth in the 
head phantom configuration. Heavy water moderator at 10 cm SSD.
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Figure 6. 1 4  Linac photoneutron source: spectral variation o f neutrons with respect to depth in the 
head phantom configuration. Head phantom helmet-like ellipsoid moderator.
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Compared to the reactor source, the medical linac source produced a substantial fast neutron component, 
and the thermal flux is spatially distributed over a wider depth (figure 6.10. and figure. 6.11). The 
medical linac therefore requires optimization to be considered for clinical BNCT treatment.
The reactor source produced 1.70x10‘2 thermal neutrons/cm2. With a 0.5 cm moderator figure 6.15, the 
medical linac source produced 7.92x10° thermal and 3.80x10° fast neutrons/cm2 at the centre of the 
brain. With a 3 cm moderator, the medical linac source produced 4.51 x 10° thermal neutrons/cm2. 
Configurations A, B, C produced thermal/fast neutron ratios of 2.300+0.005, 2.080+0.005 and 
2.330+0.004 respectively. These results show that the shorter the SSD, the better the moderation. The 
use of a custom-made helmet surrounding the head (as simulated by configuration C figure 6.14), 
however, may not be worthwhile given the slight gain in moderation.
Further optimization is expected to fine-tune medical linacs as neutron source for clinical delivery of 
BNCT using the widely-available radiotherapy linacs. The resultant lower neutron flux can be useful as
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a BNCT boost to conventional photon radiotherapy, not only for brain tumours but also thyroid, oral 
cavity, skin and hepatocellular cancers. This is further encouraged by current trends in boron delivery 
agents and protocols aiming towards lower neutron fluxes.
6.9 Conclusion
BNCT delivers a relatively low dose to healthy brain tissue , this allows for additional photon 
irradiation while maintaining a total healthy brain dose below the tolerance limit. Recent studies have 
explored the possiblity of combining conventional X-ray photon radiaion therapy with BNCT for brain 
tumours in order to enhance the efficacy of BNCT treament, with intial results suggesting significant 
therapeutic gain when BNCT is combined with an X-ray boost (Barth 2004). Yamamoto et al had also 
reported a new protocol with a combination of fractionated, extended local photon radiation, and BPA- 
and BSH-mediated BNCT for patients with supratentorial unilateral tumour. In this protocol, newly 
diagnosed glioblastoma were treated with BNCT followed by fractionated photon radiation(Yamamoto
2006).
Figure 6.15 Shapes o f dose responses for low LET and high LET radiatoins plotted on linear axes ( 
ICRP 60)
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A medcial linear aceelrator operating at high energies and with further optimization with respect to the 
otherwise unwanted neutron field can deliver fraction of the dose via BNCT to deep seated tumours 
along with normal fractinated x-ray dose. Although the neutron yield from medical linacs is not 
comparable to reactor thermal/epithermal neutron production, BNCT with its high LET can be 
administered in fractionated doses which might be as high 01* even more effective than single doses, 
figure 6.15.(ICRP 1991). “In some cases high LET radiation has been shown to have increased 
effectiveness due to low dose rate and/or fractionation, even initially i.e., an initial linear slope steeper 
for low dose rate than high dose rate. This has been termed “reverse dose-rate effect”” (ICRP 1991).
Utilising high energy medical linear accerators for BNCT will not only expand the clinical research in 
such an important yet slow growing frontier in cancer research but will make for better caring of a 
cancer patient who will be within easy access to intensive care and emergency medical staff and 
facilities should there be a need. This will also overcome the problems of public acceptance of neutrons 
and will mean more effective resource management by elminating the extra cost of sending a medical 
team off-site and the time and cost for transporting patients, let alone the cost in a reactor environment 
where clinical conditions for patient treatment will have to be established.
Medcial linear accelrators are widely used around the world and incorporating BNCT into the radation 
therapy routine will expand the use of BNCT to include devloping countries where reactor technology 
is not avaliable in the meantime.
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Chapter 7 : Conclusions and Future Work
Neutron contamination from high energy linear accelerators had been a field of thorough 
studies for the last thirty years. In this work estimation of neutron dose equivalent at the 
outer linac maze entrance was carried out using analytical techniques such as Kersey’s 
(Kersey 1979) and Wu methods (Wu 2003). Further, measurements were conducted using the 
NRD neutron survey meter and activation foils. At the outer-entrance of the maze, the dose 
equivalent as obtained with NRD was found to be about 0.04 jrSv/Gy, while calculations 
using Kersey’s method gave 0.47 |aSv/Gy. When utilising Wu and McGinley modification to 
the Kersey method, the neutron dose equivalent was estimated to be 0.085 jaSv/Gy which is a 
52% over estimation.
Activation foils were used throughout the linac maze to study the neutron fluence employing 
neutron activation techniques and subsequent gamma ray spectroscopy with a Nal(TI) 
detector. Foil activation measurements were obtained with aluminium and indium foils at
2.5 cm intervals within a moderator consisting of a block of 30 x 30 cm2 in area tissue 
equivalent material to establish fluence depth distribution in field sizes ( 0 x 0  cm2 and 20 x 
20 cm2 ) . Foils were also activated in air at 100 cm from the linac target in both the forward 
and the backward beam directions. Activation within the tissues equivalent material shows 
neutron moderation with highest thermal neutron fluence of 7.03 ± 1.30 x 106 cm'2 at 5 cm 
depth with the linac jaws open. Measurements made around the linac head in the forward 
direction (isocentre) produced a 58% increase in neutron fluence as the jaws were opened; in 
contrast, the measurements made in the backward direction were almost identical to those 
obtained when closed, showing a 1% decrease in neutron fluence for the same exposure. 
Results at the isocentre showed that neutron production is greatest with the primary 
collimation open. For a 20 x 20 cm2 field size, the maximum neutron fluence was measured 
experimentally to be 6.4 ± 1.1 x 106 cm"2 with a cadmium ratio of 2.6 ±1 .3  as opposed to
3.7 ± 1.1 x 106 cm"2 with a cadmium ratio of 2.3 ± 1 .2  when jaws closed .This work shows 
that photoneutron production increases with the size of the radiation beam in agreement with 
the Monte Carlo simulations performed by Garnica-Garza (Gamica-Garza 2005) and the
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simulations and measurements done by Kim et al. (Kim 2007). This is in contrast to 
modelling by Mao XS et al (Mao 1997) which indicated that the total neutron yield produced 
in the accelerator head is inversely proportional to the field size. This discrepancy can be 
related to the attenuation that neutrons undergo when the jaws are closed and further suggests 
that such neutron production arises from above the movable collimator and also to the 
different linac head shielding used for different linacs modelled and evaluated. Knowledge of 
such is a guarded manufacturers’ proprietary right.
Monte Carlo simulation of a linac head to study the effect of removing tbe flattening filter on 
the photonuclear production had shown an increase of neutron yield by 23 % over the whole 
spectrum when removing the flattening filter, of this 14.7% increase is in the thermal neutron 
component, 21.7% increase in tbe epithermal and 33.8 % in the fast neutron component. 
Simulations of a Zubal voxel-based anthropomorphic phantom head (Zubal 2003) to 
calculate the thermal neutron fluence from an 18 MV linac, obtained at the tumour site in the 
centre of the brain at 100 cm SSD, to be 4.39 xio7 cm'2. An addition of 1 cm heavy water 
layer around the head increases the thermal neutron fluence by 29%. Whereas a 2 cm heavy 
water layer produced a 42% increase of thermal neutron fluence at the tumour site and a 45% 
increase was achieved when we applied a 3 cm heavy water layer. Further simulations to 
compare a standard reactor neutron source for BNCT with photonuclear fluence produced 
from a 15MV linae shows that when compared to a reactor source, the medical linac source 
produced a substantial fast neutron component and the thermal neutrons are spatially 
distributed over a wider depth, when different moderators are applied. To maximize the 
thermal-to-fast-neutron ratio at the centre of the phantom, the simulation with a medical 
linear accelerator source was repeated with a 3 cm thick slab of heavy water as moderator and 
an ellipsoid of the same thickness and composition between the source and the phantom. 
Results show tbat the use of a custom-made helmet surrounding the head (as simulated with 
the ellipsoid), however, may not be worthwhile given the slight gain in moderation.
Standard photon radiation therapy for glioblastoma is usually delivered in daily fractions (5 
days/week) of 1.8-2.0 Gy to accomplish a cumulative dose of 55-60 Gy(IAEA 2001). Recent 
studies had explored tbe possiblity of combining conventional x-ray radiaion therapy with 
BNCT for brain tumours with encourging intial results suggesting significant therapeutic 
gain when BNCT is combined with an X-ray boost, (Barth R.F 2004; Yamamoto 2006). In an 
epithermal neutron beam at depth in the normal brain, the gamma component of the total dose
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can be as high as 40-50%, due primarily to the reaction in tissue. Fractionation
would be expected to be beneficial to allow for the repair of photon-induced damage to 
healthy tissue in the treatment field. Fractionation should also enable re-targeting of boron to 
a new subset of tumour cells due to the dependence of the dose distribution from the 10B (n,a) 
7Li reaction on the distribution of boron loaded drug at cellular level. This re-targeting is 
similar in concept to the repeated administration of chemotherapeutic drugs to target 
untreated cells(IAEA 2001). A medcial linear aceelrator operating at high energis and with 
further optimization of the contaminant neutron field can deliver a fraction of the dose via 
BNCT to deep seated tumours along with the fractinated x-ray dose. Although the linacs 
neutron yield is not comparable to reactor thermal/epithermal neutron production, BNCT 
with its high LET can be administrerd over fractionated doses which might be as high or even 
more effictive than single doses. Utilising high energy medical linear accerators for BNCT 
will will make for better caring of cancer patients who will be also within easy access of 
intensive care and emergency medical staff and other facilities. This if required will also 
overcome the problems of public acceptance of neutron therapy and aid more effective 
recsource mangemnt. It would, critically, also expand the use of BNCT to devloping 
countries where reactors technology is not avalible.
Further measurements should be carried out to determine neutron spectra with activation foils, 
Bonner spheres and the Lithium Gadolinium Borate (LGB) portable spectrometer, which is 
made of a composite scintillator, consisting of lithium gadolinium borate crystals in a plastic 
scintillator matrix, (Williams 2003; Williams 2004; Lewis 2007) inside the linac treatment 
room along with Monte Carlo simulation of the same linac model to give a better 
understanding of the contribution of different components that comprise the head on 
photonuclear* production, especially the linac head shielding which should help in explaining 
the variations in the literature.
One major constraint in current BNCT trials is the limited bio-distribution of 10B in targeted 
tumour tissues compared to neighbouring healthy tissue. A better preferential uptake in the 
cancerous cells will mean a reduction of neutron fluence required to deliver the same 
therapeutic dose through the capture reaction in targeted tissues. For clinical application more 
studies should be engaged in optimizing the proposed neutron beam, which may include 
enhancing the production of neutrons by the addition of extra components of high-Z materials 
at the exit port of the linac and further moderation of the produced neutron beam to tbe
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required epithermal energy in BNCT treatments. As production of neutrons from the linac is 
isotropic, beam shaping should be taken into consideration.
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